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1.1 HISTORY 
 
Marijuana has been used for centuries as a recreational drug, because of its property to 
alter sensory perception and cause euphoria. Furthermore, its application as a medicine 
has been recorded for over five thousand years as for malaria, constipation, rheumatic 
pain and female disorders. Actually, some of the earliest hemp evidence have been 
traced in rope imprints on broken Chinese pottery, which date back to 10000 B.C. 
Chinese people used the hemp plant for their clothes, their writing materials, their 
“confrontation” with evil spirits, and in the treatment of pain and diseases. 
Consequently, they were the first recorded people to experience marijuana's peculiar 
psychotropic effects. Evidence of its use have been found also in India, where Cannabis 
were adopted for the treatment of numerous diseases, such as dysentery, loss of appetite, 
poor digestion. Around 500 B.C., marijuana spread in Northern Europe, basing on an 
urn containing cannabis leaves and seeds, unearthed near Berlin. Cannabis was 
introduced to modern western medicine by W.B. O'Shaughnessy, professor at the 
University of Calcutta. In 1839, after validating many of its applications, he 
documented its analgesic properties in the treatment of rheumatism, and as a remedy for 
severe convulsions. At the same time, a French psychologist J. J. Moreau de Tours 
suggested cannabis use to treat mental illness, so that the interest in medical cannabis 
spread from Europe to America and many formulations started to be prepared, such as 
analgesic pills and sedative tablets (Fig. 1).
1
 
 
 
Fig. 1 Cannabis preparations in the early XX century  
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Beginning in the late 1960s, many academic studies have been carried out on marijuana, 
which demonstrated that cannabis effects, both psychotropic and therapeutic, are due to 
its hundreds natural components, which are classified on the basis of their chemical 
structure. The most psychoactive component of the hemp plant is tetrahydrocannabinol 
(THC), which is characterized by a terpenophenolic core, and is the parent compound of 
a major group, called cannabinoids.  
Initially, the strong hydrophobic nature of this compounds suggested that marijuana 
elicited its effects by a non-specific perturbation of cell membranes rather than by a 
specific interaction with selective binding sites. The first important finding that 
ultimately led to a rejection of this theory was the identification by Gaoni and 
Mechoulam in 1964 of the chemical structure of the (-)-trans-Δ9-THC (1, Fig. 2).2 In 
particular, they established the exact geometry through X-ray crystallography and NMR 
analysis, which led them prove that, in THC-type cannabinoids, activity resides 
exclusively in the (-)isomers with the 6aR, 10aR stereochemistry. This represented the 
starting point for the development of a whole range of synthetic analogous in the 1970s, 
that were used as tools to investigate cannabinoid system.
3
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Fig. 2 Chemical structure of Δ9-THC 
 
 
1.2 CANNABINOID RECEPTORS 
 
Studies of the biological effects of THC and its synthetic derivatives revealed a drug-
receptor interactions. Indeed, in 1990, Δ9-THC led to the identification of the first 
cannabinoid receptor, which was labelled as CB1. Three years later, in 1993, a second 
cannabinoid receptor was identified, and consequently named CB2.
4
 
CB1 and CB2 receptors are members of the superfamily of G protein-coupled receptors 
(GPCRs) that inhibit adenylyl cyclase and activate mitogen-activated protein kinase 
1. Introduction 
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(MAPK) by coupling with Gi/o proteins. They present structural omology of 44%, which 
turns into 68%, considering just the transmembrane domains (Fig. 3).
5
 
 
 
 
 
CB1 receptors are distributed abundantly and heterogeneously within the central nervous 
system (CNS), where they mediate inhibition of the release of different excitatory and 
inhibitory neurotransmitters. A high density of CB1 receptors can be found in the 
hippocampus, some olfactory regions, caudate, putamen, accumbens nucleus, substantia 
nigra, globus pallidus. Moreover, they are also present on some peripheral neurones as 
well as in certain nonneuronal tissues, like reproductive system. Given the distribution, 
their activation can affect processes such as cognition and memory, can alter the control 
of motor function, and induce signs of analgesia and hypothermia. However, it is worth 
mentioning that CB1 receptors are not widely express in the brain areas involved in 
respiration and heart rate, reason why cannabinoid drugs are not lethal. Nevertheless, 
their activation is widely associated with psychotropic effects observed with non 
selective cannabinoids, thus limiting the therapeutic potential. CB1 receptor presents 
unique properties: it has been preserved throughout evolution, considering that human, 
rat and mouse CB1 receptors have 97–99% amino acid sequence identity. This data 
reflect the important functions played by endocannabinoids in cell and system 
physiology. Another remarkable characteristic of the CB1 receptors is their high 
expression in the brain: actually, it is the most abundant GPCR in the brain, with 
densities about 50 fold above those of classical neurotransmitters. 
Fig. 3 CB1/CB2 receptor homology 
Extracellular N-terminal 
Intracellular C-terminal 
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Otherwise, CB2 was initially identified as a peripherally restricted receptor, 
predominantly expressed in cells of the immune system, especially in monocytes, 
macrophages, B-cells and T-cells and, when activated, could modulate immune cell 
migration and cytokine release both outside and within the brain. However, subsequent 
data showed that it is also expressed in both the central and the peripheral nervous 
systems, especially in microglial cells. It is likely to be involved in inflammation-
associated pathologies, such as human multiple sclerosis, osteoarthritis, rheumatoid 
arthritis, Crohn’s disease and inflammatory pain.3 
Notwithstanding, further studies proved that many cannabinoid effects cannot be 
attributed exclusively to the CB1 and CB2 receptors activation. For example, 
peripherally mediated antihyperalgesic activity persist in CB1- and CB2-gene knockout 
animals.
6
 These findings have led to the suggestion of novel cannabinoid receptors. 
Actually, in 1999, an orphan GPCR was isolated and named GPR55, with low sequence 
identity with CB receptors (< 15%). It is expressed in the brain, in the vascular 
endothelium and in the immune system. And, it can bind a wide range of endogenous, 
natural and synthetic cannabinoid ligands. Yet, its mechanism of action remains 
uncertain.
7
 In addition, application of cannabinoids seems to generate a slow inward 
current in some of the transient receptor potential (TRP) channels, including TRPV and 
TRPA.
8
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1.3 ENDOCANNABINOID SYSTEM 
 
The characterization of cannabinoid receptors opened the way for the identification of 
the respective endogenous ligands, named endocannabinoids (eCBs), which chemical 
structures are depicted in Fig. 4.  
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Fig. 4 Chemical structures of endocannabinoids 
 
The first endogenous ligand for these receptors was isolated in 1992 and it was named 
anandamide (2, AEA). It showed the same physiological and pharmacological 
properties of natural and synthetic cannabinoids, such as analgesia, motor depression, 
catalepsy. Three years later, a second endogenous intermediate was found to interact 
with CB receptors, 2-arachidonoylglycerol (3, 2-AG). Following, other endogenous 
compounds that may also bind cannabinoid receptors have been discovered and each of 
them turned out to be an arachidonic acid derivative: 2-arachidonoylglyceryl ether 
(noladin ether, 4, 2-AGE), O-arachidonoylethanolamine (5, virodhamine), N-
arachidonoyldopamine (6, NADA,) and Cis-9,10-octadecanoamide (oleamide, 7, ODA). 
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Endogenous cannabinoids, along with CB receptors and the enzymatic pathways for the 
synthesis, transport and degradation of these ligands, constitute the endocannabinoid 
system (ECS). 
Unlike classical neurotransmitters, eCBs are not stored in the cells but produced mainly 
on demand by stimulus-dependent cleavage of membrane phospholipids precursors. In 
particular, AEA is released from N-arachidonoyl-phosphatidyl-ethanolamine (NAPE), 
through an N-acyl-phosphatidylethanolamine-selective phosphodiesterase (NAPE-
PLD). AEA acts as a retrograde messenger at presynaptic cannabinoid receptors (CB1), 
where it regulates neurotransmitter release through its second transduction systems, 
mainly Ca
2+
. It is also involved in the neuromodulation of major transmitter systems, 
including dopamine, at postsynaptic cells, where it regulates synaptic plasticity through 
its modulation of potassium (K
+
) channels. It is also involved in the neuromodulation of 
major transmitter systems at postsynaptic cells, where it regulates synaptic plasticity 
through modulation of K
+
 channels and MAPK. Moreover, AEA is capable of 
interacting with other targets, such as the TRPV1 receptor and the peroxisome 
proliferator-activated receptors (PPARs).
9
 Recently, it has been suggested a different 
biosynthetic pathway, independent from NAPE-PLD, but involving a type-A2 
phospholipase (PLA2), which hydrolyzes NAPE, releasing fatty acids and N-
arachidonyllisophosphatidylethanolamine (NA-lysoPE), an additional precusor of AEA. 
On the other hand, 2-AG is produced from the hydrolysis of diacylglycerols (DAGs) by 
DAG lipases (DAGLs) specific for sn-1 position. The molecules of DAG, which must 
possess an esteric function at sn-2 position, can be produced from the hydrolysis either 
of phosphoinositides (PI), catalyzed by a Ca
2+
-dependent phospholipase C (PLC), or of 
phosphatidic acid (PA) catalyzed by a specific Ca
2+
-dependent PA hydrolase.
10
  
Subsequently, eCBs are transported in both directions through cell membrane by 
diffusion or selective transport by the putative endocannabinoid membrane transporter 
(EMT): a process that is fast rate, temperature-dependent, saturable, bidirectional and 
selective. In the extracellular space they can interact with cannabinoid receptors or be 
internalized and degraded. Endocannabinoid signalling is closed by a two-step process 
that includes transport into cells and hydrolysis by two specific enzymatic systems. 
AEA is metabolized by fatty acid amide hydrolase-1 (FAAH) in arachidonic acid and 
ethanolamine, while 2-AG is hydrolized by monoacylglycerol lipases (MAGLs) into 
arachidonic acid and glycerol. FAAH is a 64kDa integral membrane protein, which 
displays optimal activity at alkaline pH (about 9). It is composed by 597 amino acids 
and is rich in glycine and serine residues. Immunohistochemical studies confirmed that 
1. Introduction 
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the expression of this enzyme in different brain areas is directly correlated to CB1 
receptor density.
11
 X-ray crystallography studies helped determine the enzyme structure 
and, consequently, led to the identification of binding sites. FAAH, unlike other 
amidases, does not use catalytic serine-histidine-aspartate triad, but it presents a serine-
serine-lysine sequence, in which Ser
241
 acts as a nucleophile, Ser
217
 stabilizes the 
negative charge and the Lys
142
 acts as a base.
12
 MAGL is a 33 kDa protein that belongs 
to the serine hydrolase family and presents a typical catalytic triad made of Ser
122
, 
His
269
 and Asp
239
. It is highly expressed in those areas of the brain rich in CB1 
receptors.
13
 
Moreover, recent experimental studies confirmed that AEA and 2-AG can function as 
substrate for cyclooxygenase-2 (COX-2) and some lipoxygenases. Actually, COX-2 
efficiently oxygenates 2-AG and AEA into prostaglandin ethanolamides and 
prostaglandin glycerol esters respectively (Fig. 5).
14
 
 
 
Fig. 5 Cannabinergic transmission
15
 
 
AEA and 2-AG exhibit different binding properties and intrinsic activity at CB 
receptors. Actually, AEA behaves as a partial agonist at both receptors, with higher 
affinity for type-1 receptor. Alternatively, 2-AG is a full agonists at both receptor, but 
displays lower affinity than AEA.
16
 
2-AGE is an ether-derivative of 2-AG, which binds mostly to CB1 and very weakly to 
CB2 receptor. However, it has been demonstrated an opposite effect, because it can 
induce the inhibition of μ-opioid receptor through CB2 receptor activation. It is also 
capable of activating PPAR-α receptor and presents more stability in vivo than both 
1. Introduction 
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AEA and 2-AG, which are rapidly hydrolyzed. Virodhamine acts as a partial agonist on 
CB1 receptors, even though it can be an antagonist of this receptor at higher 
concentrations. It also acts as full agonist on CB2 receptor and can activate PPAR-α 
receptor and GPR55. NADA is an endogenous ligand of CB1 and TRPV1 receptors. It 
can act as either an endovanilloid or endocannabinoid, depending on which one it 
interacts with. Moreover, it is able to activate PPAR-γ. Finally, Oleamide acts as a full 
agonist of cannabinoid receptors with higher selectivity for the CB1 receptor.
9
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1.4 CANNABINOID RECEPTOR LIGANDS 
 
The ubiquitous distribution of the ECS correlates with its role as a modulator of 
multiple physiological processes. Synthetically produced compounds which display 
affinity to CB receptors may act either as agonists, enhancing the activity of eCBs, or as 
antagonists, preventing the binding of eCBs, and consequently inhibiting the activity of 
the ECS. Agonistic behaviour can be exploited for a wide set of applications: hypnotic, 
analgesic, antiemetic, antiasthmatic, antihypertensive, immunomodulatory, anti-
inflammatory, neuroprotective and so on. On the other hand, cannabinoid receptor 
antagonism might be exploited in conditions with enhanced eCBs signalling, as drugs 
and alcohol addiction status.
17, 18 Anyhow, it is possible to modulate ECS transmission 
and metabolism also by targeting the biosynthetic and hydrolytic enzymatic pathways 
(FAAH and MAGL inhibitors) or acting on the putative EMT.  
 
1.4.1 Agonists 
 
According to the International Union of Pharmacology
3
, cannabinoid receptor agonists 
can be classified in classical and non classical cannabinoids, aminoalkylindoles and 
eicosanoids (eCBs). Classical cannabinoids are defined by the characteristic tricyclic 
terpenophenolic moiety of the parent compound 1, 9-THC, and are also called 
phytocannabinoids. Compound 1 is a nonselective agonist that binds to both CB 
receptors, with a similar affinity of approximately 40 nM.
19
 It displays a wide range of 
therapeutically interesting effects, such as analgesia, anti-inflammatory, 
immunosuppressive, anticonvulsive, antiemetic, and orexigenic properties, albeit its 
employment has been restrained because of its psychotropic effects and drug abuse. The 
commercially available derivative of THC, known as Marinol
®
, is currently approved in 
the United States for treating nausea and vomiting in patients receiving chemotherapy. 
Its synthetic analogue Nabilone (8, Fig. 6), marketed as Cesamet
®
, was approved in 
1985 by the Food and Drug Administration (FDA) for treatment of chemotherapy-
induced nausea and vomiting and for chronic pain management. Cannabidiol (CBD, 11, 
Fig. 7), on the other hand, lack the terpenophenolic core, and actually is a non-
psychotropic phytocannabinoid, that displayed strong antioxidant, neuroprotective, anti-
ischemic and antiinflammatory effects. Interestingly, CBD displays very low affinity 
towards CB recpetors, whereon it acts as an antagonists. Surprisingly, emerging data 
from several studies has led to the recognition that CBD couples positively with the 
1. Introduction 
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putative new cannabinoid receptor GPR55 and, moreover, it can activate some 
ionotropic receptors, like TRPV and TRPA.
8
 Its commercially available formulation, 
Sativex
®
, is an oromucosal spray which delivers a 1:1 ratio of CBD and THC and it can 
be prescribed for neuropathic and oncological pain. 
Starting from THC, different substitutions on the critical positions of the tricyclic 
scaffold (C-1, C-3, C-9) have been made, that led to the synthesis of numerous 
compounds. The most representative ones are described in Fig. 6.  
 
O
O
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8, Nabilone
O
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9, HU-210
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10, JWH-133  
Fig. 6 Chemical structures of Classical cannabinoids 
 
Synthetic cannabinoid HU-210 (9) displayed significantly enhanced affinity for both CB 
receptors, producing many of the same pharmacological effects as 1. Moreover, it has 
been demonstrated that the removal of C-1 hydroxyl group enhances the affinity for 
CB2 rceptor.
18
 Actually, in the des-hydroxyl series, compound 10, known as JWH-133, 
showed 200 fold higher activity towards type-2 CB receptor, making it one of the most 
potent of the series.  
Modifications of the terpenophenolic nucleus generated the so-called non classical 
cannabinoids.  
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Fig. 7 Chemical structures of Nonclassical cannabinoids 
 
This class of molecules include bicyclic or tricyclic analogues of THC that possess a 
replacement of the pyranyl ring or its entire loss. The most representative compound in 
this series (Fig. 7) is 12, CP-55,940, which behaves as a full agonist with high affinity 
for both CB1 and CB2 receptors. Its radiolabelled [
3
H] isotope is among the most widely 
employed reference compound in the characterization of cannabinoid ligands. 
Compound 13, named HU-308, exhibited excellent selectivity for the CB2 receptor 
(>440 fold) and showed anti-inflammatory and peripheral analgesic activity in a 
formalin-induced inflammation model in mice.
20
 
In the early 1990s, it has been identified the first novel class of totally synthetic 
cannabinoid derivatives, charachterized by an aminoalkylindole core. These molecules 
present an indole scaffold substituted by a lipophilic aroyl group at C-3 and an 
aminoalkyl side chain at N-1 (Fig. 8). 
O
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14, WIN55212-2 15, AM1241
N
O
16, JWH-015  
Fig. 8 Chemical structures of Aminoalkylindole derivatives  
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Compound 14, labelled as WIN55212-2, is one of the most studied synthetic 
cannabinoids in the series and has been widely utilized, as [
3
H] isotopic form, for 
pharmacological investigations in cannabinoid research.
21
 The aminoalkylindole series 
is probably the most studied among the synthetic cannabinoids. Actually, various 
compounds in this group are noteworthy, like 15, AM1241, which displays notable CB2 
selectivity (SI > 80). Collectively, the indolic cannabinoids presented small substituents 
at C-2 of the indole core, because larger groups usually led to a loss in activity. 
Compound 16, JWH-015, also selective for the CB2 subtype, showed also 
immunosuppressive properties.  
Regarding C-3 position, although many of the synthetic cannabinoids have generally 
favoured 3-naphthoyl or 3-aroyl groups, a distinct chemical series carrying a tetramethyl 
cycloalkyl ketone has been developed, which displayed an interesting pharmacological 
profile. Compound 17 (A-796260) is a notable example, which revealed receptor 
affinity and selectivity about 192-fold over CB1 receptor. Subsequently, extensive SAR 
studies have been carried out on the cycloalkyl ketone series, wherein side chain 
variations at the N-1 position led to potent and highly selective CB2 agonists (18, Fig. 
9).
22
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Fig. 9 Cycloalkyl ketone and Carboxamide derivatives 
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Afterwards, substitution of the ketone moiety with a bulky amide residue led to the 
formation of new indole-derived cannabinoid receptor ligands (19-20).
23
 Compound 19 
displayed an excellent CB2 agonist behaviour, suggesting that a carboxamide residue 
could be involved in receptor binding. 
Actually, several independent groups reported CB2 selective 6,6-fused heterocyclic 
modulators which maintained the amide function. A series of naphthyridines (21) and 
quinolines (22) were synthesized and analyzed for their cannabinoid activity (Fig. 10).
24
 
Compound 22 provided the best pharmacological profile, with great affinity and 51-fold 
higher selectivity against CB1 receptor. These novel series demonstrated significant 
analgesic effects in a mouse formalin test of acute peripheral and inflammatory pain.  
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Fig. 10 Naphtyridine and Quinoline derivatives as CB2-receptor agonists 
 
1.4.2 Antagonists 
 
The developing of CB receptors antagonists aims to attenuate eCBs tone in those 
pathologies whose etiology involves high ECS activation. These medical conditions 
include eating disorders, especially obesity and associated cardiometabolic problems 
and drug addiction. To date, numerous CB antagonists have been synthesized, which are 
characterized by different chemical nucleus and are depicted in Fig. 11.  
Specifically, the first CB1 receptor anatagonist 23, SR141716A, known as Rimonabant 
(Acomplia
®
), presents a diarylpyrazole structure. It binds with significantly higher 
affinity to CB1 rather than CB2 receptors, and lacks significant affinity for non-
cannabinoid receptors. It behaves as an inverse agonist and showed clear clinical 
efficacy for the treatment of obesity and alcohol and tobacco addiction status.  
LY320135 (24) presents a benzofuranic nucleus. It displays lower affinity to CB1, 
compared to Rimonabant, but greater affinity to muscarinic, 5-hydroxytryptamine (5-
HT)2, histamine, dopamine receptors and adrenoreceptors, at different concentrations. 
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AM251 (25) and AM281 (26) are both characterized by a dyarylpyrazole core, like 
Rimonabant. They showed respectively three and eight times less potency than 
Rimonabant and both compounds proved higher affinity for CB1 than CB2 receptors.
25
  
Moving to CB2-receptor antagonists, they could have therapeutic potential in 
inflammatory disorders, arthritis and autoimmune diseases. However, their development 
is too limited to analyze their pharmacological profile. The most important known CB2-
receptor antagonists are the diarylpyrazole 27 (SR144528) and the aminoalkylindole 6-
iodopravadoline 28, labelled as AM630. (Fig. 10). Compound 27 showed great 
selectivity towards CB2 receptor in both in vitro and in vivo assays, with a SI higher 
than 700. Likewise, AM630 is a potent and selective compound which behaves as an 
inverse agonist for CB2, with a Ki of 32.1 nM, and displays a selectivity index over 
165.
26
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Fig. 11 Chemical structures of the most representative CB receptors antagonists  
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1.4.3 FAAH inhibitors 
 
An attractive alternative to the preparation of CB receptors ligands is the development 
of FAAH inhibitors (Fig. 12), which raise the endogenous levels of eCBs by blocking 
their hydrolysis. This approach may avoid the undesired side effects of a conventional 
drug-receptor interaction. 
To date, a remarkable series of potent, selective, and efficacious FAAH inhibitors have 
been disclosed and classified in reversible and irreversible compounds, basing on their 
mechanism of action. Many of them have been exploited as a tool to characterize the 
enzyme, define its mechanism of fatty acid amide hydrolysis, and validate it as a 
therapeutic target for the treatment of pain and inflammation.  
The first class is characterized mostly by a -ketoheterocycle scaffold that binds to 
FAAH by reversible hemiketal formation with a serine residue of the active site. 
However, additional classes of reversible FAAH inhibitors have been reported later, 
including substituted (thio)hydantoins and imidazolidinediones, oxime, enol 
carbamates, benzothiazoles, benzoxazoles, arylboronic acids, selected sulfonamides, 
cyclic ureas and lactams. The most representative reversible FAAH inhibitor is 
compound 29, OL-135, which is reversible, competitive and selective. It produces 
analgesic, antinociceptive and anti-inflammatory activity in various preclinical animal 
models. However, much research groups focused on developing irreversible covalent 
FAAH inhibitors, in order to achieve long acting pharmacological activity in vivo. 
Carbamate-based inhibitors are the most studied class of irreversible inhibitors. Its lead 
compound is 30 (URB597), which binds to the active site and induces a carbamylation 
of Ser
241
, inactivating the enzyme. Analogously to reversible inhibitors, also the 
irreversible class has been increased with a lot of different compounds: actually, 
research in this field is still growing.
27
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Fig. 12 Chemical structures of the most representative FAAH inhibitors 
  
1. Introduction 
17 
1.5 THERAPEUTIC TARGETS 
As introduced previously in this work, 
Cannabis and its derivatives have always 
showed great potential as therapeutic 
agents (Fig. 13). In the last decades, 
scientists primarily studied cannabis 
ability to alleviate various disease 
symptoms, such as the nausea associated 
with cancer chemotherapy. Today, 
research is directed towards the potential 
role of cannabinoids, investigating their 
property to moderate autoimmune 
disorders, such as multiple sclerosis 
(MS), rheumatoid arthritis, and 
inflammatory bowel disease, as well as their role in the treatment of neurological 
disorders, that is to say Alzheimer’s disease (AD) and amyotrophic lateral sclerosis 
(ALS). Moreover, many cannabinoids produce inhibition of pain responses and can be 
useful in management of glaucoma, bronchial asthma, inflammatory disorders and 
cancer.
28
 
Some of the most widespread uses of cannabis derivatives are analyzed below. 
 
1.5.1 Nausea and vomiting 
 
The development of chemotherapy drugs has improved cancer treatment. However, this 
kind of compounds present remarkable side effects, such as nausea and vomiting, which 
may last for several days. These symptoms determine a reduction of patient compliance, 
interfering with therapy success. Since the discovery of the ECS, considerable 
researches confirm that cannabinoids serve as effective anti-emetics. In ferret and shrew 
models, the site of action has been identified in the emetic area of the brainstem and the 
dorsal vagal complex. It is has been confirmed that their anti-emetic properties are 
mediated by CB1 receptors; actually, CB1 antagonists SR-141716 and AM251 
respectively potentiated the strength of toxin-induced vomiting in animal models. Yet, 
also CBD, which does not possess affinity for type-1 cannabinoid receptor, can 
produces anti-emetic effects. Consequently, further researches need to be carried on 
about this property.
29
   
Fig. 13 Therapeutic targets of cannabinoids 
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1.5.2 Neurodegeneration and neuroprotection 
 
Cannabinoids showed neuroprotective and anti-proliferative properties. Recently, many 
research groups have demonstrated the involvement of ECS in the protection against 
acute or chronic brain damage. In particular, phytocannabinoids, synthetic and 
endogenous cannabinoids showed neuroprotection both in vitro and in vivo cytotoxic 
models of ischemia and head trauma. In addition, cannabinoids are also neuroprotective 
in several chronic neurodegenerative diseases such as Parkinson’s disease (PD), 
Huntington’s disease (HD), ALS, AD and MS, which present excitotoxicity, 
mitochondrial dysfunction, inflammation and oxidative stress. There are few molecular 
mechanisms underlying these properties. Actually, they include some processes not 
mediated by CB receptors directly, but involving N-methyl-D-aspartate (NMDA) 
receptor antagonism, and others that are definitely mediated by either CB1 or CB2 
receptors, which are able to reduce glutamate release, calcium influx and inflammation, 
while on the other hand, can stimulate γ-aminobutyric acid (GABA) activity.30  
 
1.5.3 Appetite and obesity 
 
Cannabis ability to stimulate appetite has been known all along its widespread. Recent 
experiments using synthetic or natural cannabinoid agonists have confirmed the role of 
the ECS as a modulator of food intake. However, the molecular mechanism is still far 
from being understood, and consequently its elucidation is the cornerstone of many 
researches. Based on these findings, dronabinol was approved by FDA in 1992 for the 
treatment of AIDS-related anorexia, a syndrome which occurs in about 18% of AIDS 
patients and which decreases the quality of life and the chance of recovery. 
Interestingly, the first potent and selective CB1 cannabinoid antagonist, Rimonabant, 
was able to reverse the hyperphagia induced by 9-THC and also determined changes in 
ingestive behaviours when administered alone. These results suggested to exploit 
cannabinoid antagonists for the treatment of eating disorders and, above all, obesity. 
Moreover, based on preliminary pharmacological studies, CB1 antagonists may also be 
useful for the treatment of alcoholism, and in smoking cessation. Actually, clinical 
studies with Rimonabant have already shown increased tobacco-smoking abstinence as 
well as prevention of the secondary weight gain often associated with smoking 
cessation.   
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1.5.5 Pain 
 
Pain is a weakening condition that responds poorly to available therapies. It is generally 
associated with nerve injury, toxic insults and disease states. Consequently, drug 
discovery efforts have been directed toward the identification on novel analgesic targets. 
The role of cannabinoids in pain modulation has been systematically studied since the 
XIX century, although the mechanism underlying the analgesic effects was barely 
understood until the characterization of CB receptors. Actually, cannabinoids suppress 
allodynia and hyperalgesia in different neuropathic pain models, through CB1 and CB2 
specific mechanism. These studies have not only provided a detailed understanding of 
the network of neural and inflammatory cells, but, moreover, have led to the 
comprehension of the physiological role of eCBs in pain regulatory circuits. 
Nevertheless, the psychoactive effects mediated by central CB1-activation, represent an 
important boundary in pharmacotherapies. It follows that novel approaches to minimize 
unwanted side effects, such as selectively targeting CB2-receptor, represent a valuable 
direction for future evaluations. 
 
1.5.6 Cancer 
 
The therapeutic effects of cannabinoids on some cancer-related conditions, such as 
emesis, nausea, depression, muscle tension, insomnia, chronic pain and loss of appetite, 
have been widely investigated. The anti-neoplastic activity of 9-THC and its 
derivatives was first observed in the early 1970s, but no further investigations were 
performed on this topic until recently. 
Several natural (THC and CBD), synthetic (WIN-55, 212-2 and HU-210) and 
endogenous cannabinoids (AEA and 2-AG) produce antiproliferative effects on a wide 
spectrum of tumour cells.
31
 More importantly, cannabinoid administration to nude mice 
delays the growth of various tumours, including lung carcinomas, gliomas, thyroid 
epitheliomas, skin carcinomas and lymphomas. 
It has been proved that eCBs play a protective role in the early stages of tumour 
development. In a recent study, indeed, AEA and the corresponding biosynthetic 
precusors levels have been analyzed in various human tumours. In most cases, cancer 
tissues presented higher levels of AEA compared to the healthy tissues. As evidence, 
several tumour cell lines demonstrated the same peculiarities: the ability to synthesize 
eCBs, the expression of CB receptors and the expression of their biosynthetic enzymes, 
1. Introduction 
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confirming the involvement of ECS in the control of cell proliferation. Moreover, it has 
been demonstrated that AEA and 2-AG inhibit the cell proliferation in breast cancer and 
prostate cancer, through CB1 stimulation. Subsequent findings have than reported the 
inhibitory action of cannabinoids on the growth of glioma cell lines, thyroid 
epitheliomas, and mast cell lymphomas. More recent studies have focused the attention 
on the effect of eCBs in angiogenesis and formation of metastases. In conclusion, the 
use of cannabinoid receptor ligands might not only slow down the growth of tumours 
via multiple mechanisms, but at the same time also attenuate the related disorders. 
However, many efforts still need to be done in this research area.
32
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To date, CB2 receptor agonists have gained attention as potential therapeutic targets in 
the management of numerous diseases. It is necessary to achieve selectivity towards this 
receptor subtype in order to avoid the characteristic central side effects, mediated by 
CB1-activation. 
The purpose of this project has been the design, the synthesis and the biological 
evaluation of new CB2-selective agonists. 
We designed a new chemical structure (Fig.14) that included the primary characteristics 
of the most active and selective CB2-receptor agonists (14, 22). Initially, we decided to 
prepare a series of diazepinoquinoline (46-52) and pyridoquinoxaline (53-56) 
derivatives, basing on their easy preparation. Actually, we optimized the synthetic 
routes, obtaining the formation of the tricyclic scaffold in just three steps.
33
 Then, we 
synthesized different lipophilic carboxamide derivatives, in order to value the influence 
of carboxamide moiety on the receptor affinity.  
The novel synthesized compounds have been evaluated in receptor binding assays, 
using [
3
H]CP,55-940 as radioligand. The preliminary obtained data were discouraging, 
giving affinity values higher than 150 nM.  
Consequently, we needed to improve the molecular core, thus we designed a new hybrid 
chemical structure defined by a oxazinoquinoline scaffold (Fig. 15). 
The first synthesized examples of this novel series (69-80) showed really promising 
results (Table 2) which led to explore the novel nucleus, by investigating the effect of 
different substitutions at the crucial positions (C-2, C-3, C-6, C-8, C-9, C-10) on the 
affinity for CB receptors.
34
 
The novel oxazinoquinoline derivatives were tested in competition binding assays 
towards both rat and human CB receptors. Affinity values (Ki, nM) were used to 
calculate the selectivity of these novel compounds versus CB2 receptors. The ligands 
were also examined in cAMP assays on hCB2 (Chinese hamster ovary) CHO cells, in 
order to evaluate the inhibition of the adenylyl cyclase activity and consequently the 
potency values (IC50, nM). 
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Fig. 14 Rational design of diazepinoquinoline and quinoxaline derivatives.  
Baraldi, P.G.; Ruggiero, E.; Agahazadeh Tabrizi, M. J. Het. Chem. 2014, 51, 101-105 
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Fig. 15 Rational design of oxazinoquinoline compounds 
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The 2,8-dioxo-1,2,3,4-tetrahydro-8H[1,4]diazepino[3,2,1-ij]quinoline-7-carboxamide 
46 was prepared as described in Scheme 1. Starting o-phenylenediamine 31 was 
condensed with acrylic acid to yield the benzodiazepin-2-one 32 in 68% yield.
35
 
Following reaction with diethyl ethoxymethylene malonate (DEEM) at 140 °C led to 
the formation of the methylenemalonate derivative 33 in 90% yields. Cyclization of 33 
in polyphosphoric acid (PPA) provided the tricyclic derivative 34 in 95% yields. After 
hydrolysis of the ethyl ester functionality of compound 34 in acidic conditions, the 
resulting carboxylic acid 35 was converted into the target carboxamide 46 under peptide 
coupling conditions.  
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a Reagents and conditions: 
(i) acrylic acid, HCl conc., H2O, 70 °C, 3 h; 
(ii) DEEM, 140 °C, 2 h; 
(iii) PPA, 140 °C, 1 h; 
(iv) HCl 20%, CH3COOH, 100 °C, 4h; 
(v)cyclohexylamine, DIEA, HBTU, DMF, rt, 16 h.  
 
The synthesis of diazepinoquinoline derivatives 47-52 was initially realized as outlined 
in Scheme 2. 2,3-dihydro-1H-benzo[b][1,4]diazepines 36a-d were prepared by heating 
o-phenylenediamine 31 with appropriate ketones in the presence of 2 mol% N-
bromosuccinimide (NBS) as a catalyst, which mechanism is depicted in Fig. 16.
36
 
Subsequent addition-elimination reaction with DEEM did not afforded 38a-d as 
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expected, but determined hydrolysis of the iminic carbon nitrogen double bond, yielding 
diethyl 2-[(2-aminophenylamino) methylene]malonate 37. 
 
Scheme 2 
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a Reagents and conditions: 
(i) appropriate ketone, 10mol % NBS, 40 °C, 4h; 
(ii) DEEM, 140 °C, 2 h.  
 
The alternative route to prepare the tricyclic scaffold is shown in Scheme 3. Sodium 
borohydride (NaBH4) was used to reduce the carbon nitrogen double bond of 
compounds 36a-d in 75-80% yield.
37, 38
 Saturation of prochiral imine 36c provided a 
mixture of syn/anti diastereomers (3:1) that were separated by column chromatography 
on silica gel to furnish the syn-isomer 38c as major diastereomer. The syn-conformation 
was confirmed by NMR studies, such as NOEDIFF experiments, that showed the 
presence of NOE enhancements between H-3 ( = 2.39 ppm) and H-4 ( = 4.43 ppm) 
protons. Moreover, the saturation of H-4 ( = 4.43 ppm) protons did not reveal NOE 
with the cyclopentyl hydrogens.  
Regarding compound 38d, surprisingly, hydrogenation with NaBH4 gave only the syn-
diastereomer. For compound 38d too, the configuration was assessed through 
NOEDIFF experiments. The saturation of C-2 methyl ( = 1.64 ppm) protons resulted in 
NOE enhancements at H-4 ( = 4.22 ppm), suggesting that the methyl at C-2 and H-4 
should be oriented in the same direction. The 
1
H and 
13
C NMR data of this compound 
are completely consistent with those reported in literature for the sin-isomer.
39
 
Condensation with DEEM at 140 °C for 2 h yielded the 5-methylenemalonate 
derivatives 39a-d (85-90%). The regioselective addition of DEEM at N-5 position was 
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preferred because of the less steric hindrance present at the 4-position rather than at the 
2-position. Subsequently, cyclization reaction with PPA at 130°C in 30 minutes gave 
compounds 40a-d in 35-40% yields.
40, 41
 The chemical identity of ethyl carboxylate 
derivatives 40a-d has been established by 
1
H NMR and MS spectra, while NMR 
NOEDIFF studies were conducted in order to analyze the C-4 substituents. Actually, 
compounds 40a-d showed NOE enhancement from the position 6-CH to the 4-CH 
protons on the benzodiazepinoquinoline nucleus, confirming the addition of 
methylenmalonate chain on the NH close to the less steric hindrance carbon atom.  
Eventually, hydrolysis of the ethyl ester derivatives, followed by coupling with 
appropriate amines, gave the desired compounds 47-52. 
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a Reagents and conditions: 
(i) appropriate ketone, 10mol % NBS, 40 °C, 4h; 
(ii) NaBH4, CH3OH, rt, 2h;
(iii) DEEM, 140 °C, 2 h.
(iv) PPA, 140 °C, 1 h; 
(v) HCl 20%, CH3COOH, 100 °C, 4h; 
(vi) amine, DIEA, HBTU, DMF, rt, 16 h, or amine, EDC, HOBt, DMF, rt, 16h.
a: R = R1 = methyl, R2 = H
b: R = R1 = ethyl, R2 = H 
c: RR1 = cyclopentyl, R2R = cyclopentyl
d: R =phenyl, R1 = methyl, R2 = H
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Fig. 16 Mechanism for NBS catalyzed reaction. The amine of o-phenylenediamine is activated by NBS in 
order to attack the carbonyl group of the ketone and providing intermediate diimine. Subsequently, a 1,3-
shift of the hydrogen attached to the methyl group occurs to form an isomeric enamine, which cyclizes to 
afford the diazepine ring. 
 
 
The synthesis of ethyl pyrido[1,2,3-de]quinoxaline-6-carboxamide derivatives is 
depicted in Scheme 4. Only few papers reported the preparation of 9-substituted-3,4-
dihydroquinoxalin-2(1H)-ones and, generally, their synthesis has been developed 
starting from 2-nitrobenzenamine or 1-fluoro-2-nitrobenzene
 
as starting materials.
42-44
 
We optimized a new synthetic approach from o-phenylenediamines, that reacted with 2-
bromoacetate in presence of triethylamine (TEA) at 80°C
 
to give the 3,4-
dihydroquinoxalin-2-(1H)-ones (42a-d) in 80% yields.
43
 Preparation of target 
compounds 53-56 proceeded analogously to the synthesis of previous tricycles, by 
addition of DEEM to 3,4-dihydroquinoxalin-2-(1H)-one derivatives 43a-d, followed by 
cycloacylation in PPA at high temperature to yield compounds 44a-d. Hydrolysis of 
ethyl 1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-carboxylate 44a-d 
gave the correspondent carboxylic acids 45a-d in high yields. Finally, intermediates 
45a-d were converted into the desired compounds 53-56, as shown previously.  
The position of halogens 9-F, 9-Cl on the quinoxaline core in compounds 44b and 44c 
was confirmed by 
1
H NMR analysis. Moreover, 
19
F NMR resonance was used to 
resolve fluorine derivative 44b: it displays three signals at -114.070, -114.094, -114.119 
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ppm with scalar couplings of equal intensity (JHF (H-8) = JHF (H-9) = 10 Hz), which 
confirm the presence of fluorine residue on C-9.  
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a, R = R1 = H
b, R = F; R1 = H
c, R = Cl; R1 = H
d, R = R1 = CH3
a Reagents and conditions: 
(i) ethyl 2-bromoacetate, TEA, DMF, 80 °C, 3h; 
(ii) DEEM, 140 °C, 2 h;
(iii) PPA, 140 °C, 1 h;
(iv) HCl 20%, CH3COOH, 100 °C, 4h; 
(v) adamant-1-ylamine, DIEA, HBTU, DMF, rt, 16 h.  
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Each of the newly synthesized compounds was examined in [
3
H]CP-55,940 competition 
binding experiments for their affinity and selectivity towards the rat and human 
recombinant CB1 and CB2 receptors (Table 1). 
Initially, the choice of the three kind of scaffolds was due to their manageable 
preparation. Thus, we synthesized the new compounds 46-56, keeping the lipophilic 
carboxamide moiety, essential for the receptor binding.
45
  
Unfortunately, among the three developed series, only 2,3,4,8-tetrahydro-8-oxo-1H-
[1,4]diazepino[3,2,1-ij]quinoline-7-carboxamide derivatives (47-52) showed activity 
towards CB receptors, while compound 46, 53-56 resulted totally inactive. 
In particular, introduction of an alkyl residue on the diazepine ring, such as methyl, 
ethyl, or cyclopentyl group, provided affinity for CB2 receptors, with a reasonable 
selectivity. The best results in this series were obtained with compound 50, with hKi 
CB2 = 153 nM and SI > 65. On the other hand, replacing the aliphatic moiety with an 
aromatic residue, like the phenyl ring (48-49), gave a total loss of activity.  
On the basis of these results, we hypothesized that the inactivity was due to the poor 
lipophilicity of these scaffolds (cLog P < 2.5). Actually, protein–ligand binding 
partially depends on lipophilic interactions, and the optimal cLog P for a class of 
ligands will depend on the nature of target protein. Since the endogenous ligands for the 
CB2 receptor are highly lipophilic fatty acid derivatives, a higher range of cLog P 
values is required.
46
 
Consequently, we decided to change the diazepine/piperazine cycle of the molecular 
core, designing a new hybrid chemical structure defined by a oxazinoquinoline scaffold 
(Fig.10).  
    
  
Table 1. Affinity (Ki, nM) and Selectivity Index (SI) of the Novel CB Compounds 46-56 on Rat and 
Human CB1 and CB2 Receptors
a
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Cpd R1 R2 R3 rat CB1
b
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c
 hCB1
d
 hCB2
e
 SI 
14 (R)-(+)-WIN55,212–2 15.6 ± 1.4 7.58 ± 0.72 12.4 ± 1.3 4.53 ± 0.42 2.74 
46 
  
adamant-1-yl  >10000 (1%) >10000 (1%)  >10000 (1%) >10000 (1%) 
 
47 CH3 CH3 adamant-1-yl 5250 ± 556 213 ± 22 4540 ± 425 165 ± 14 27 
48 ethyl CH3 adamant-1-yl >10000 (1%) 194 ± 13 >10000 (1%) 153 ± 12 >65 
49 ethyl H cyclohexyl >10000 (1%) 248 ± 16 >10000 (1%) 204 ± 15 >49 
50 cyclopentyl cyclopentyl adamant-1-yl >10000 (1%) 3156 ± 282 >10000 (1%) 2852 ± 254 >3.5 
51 phenyl H adamant-1-yl >10000 (1%) >10000 (15%) >10000 (1%) >10000 (21%) 
 
52 phenyl H cyclohexyl >10000 (1%) >10000 (1%) >10000 (1%) >10000 (1%) 
 
53 H H adamant-1-yl >10000 (1%) >10000 (1%) >10000 (7%) >10000 (1%) 
 
54 F H adamant-1-yl >10000 (1%) >10000 (2%) >10000 (1%) >10000 (3%) 
 
55 Cl H adamant-1-yl >10000 (1%) >10000 (1%) >10000 (1%) >10000 (1%) 
 
56 CH3 CH3 adamant-1-yl >10000 (1%)  >10000 (1%) >10000 (1%) >10000 (1%)   
aThe data are expressed as the mean ± SEM of n = 4 independent experiments. bThe affinity values were calculated by using [3H]CP-55,940 as a 
radioligand on rat brain for CB1 receptors. 
cThe affinity values were calculated by using [3H]CP-55,940 as a radioligand on rat spleen for CB2 receptors. 
dThe affinity values were calculated by using [3H]CP-55,940 as a radioligand on human CB1 CHO membranes. 
eThe affinity values were calculated by 
using [3H]CP-55,940 as a radioligand on human CB2 CHO membranes. 
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The desired 7-oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides 69-109 were 
developed following two synthetic strategies, based on the availability of the α-halo 
ketone or amino alcohol necessary to generate the desired substitutions on the oxazine 
nucleus. Racemic compounds 69-83 and 92-100 were prepared as outlined in Scheme 5. 
Deprotonation of 2-nitrophenols 57a-c, and subsequent alkylation with the appropriate 
α-halo ketones led to the formation of nitro ketones 58a-h. In the second step, reduction 
of the nitro function of 58a-h using 10% palladium-on-carbon in methanol (or 
methanol/THF (85:15) for 3-aryl derivatives) provided the benzoxazines 59a-g,i,j by a 
simultaneous reduction–reductive amination sequence. Apparently, compounds 59i and 
59j were formed as a consequence of a ring-opening of the cyclopropyl precursors 58g 
and 58h, respectively. Following reaction with DEEM at 140 °C gave the corresponding 
methylenemalonate derivatives 60a-g,i,j in 70–90% yields. Intermediates 60a-g,i,j were 
thermally cyclized in PPA for 1 h, providing the oxazinoquinoline ester derivatives 61a-
g,i,j in high yields.
47
 Saponification of esters 61a–g,i,j with sodium hydroxide furnished 
the carboxylic acids 62a-g,i,j, which were converted into the target carboxamide 
derivatives 69-83 and 92-100, by an amidation reaction with the appropriate amines 
under peptide coupling conditions. 
Alternatively, the synthesis of compounds 84-91, 101-104, 108-109 was realized by the 
procedure utilized for the preparation of optically active ofloxacine (Scheme 6).
48
 Ethyl 
3-oxopropanoate derivatives (64a-c) were prepared starting from the corresponding 
benzoic acids (63a-c) by reaction with carbonyldiimidazole (CDI) in THF to give the 
imidazolide, and consequent condensation with the magnesium salt of monoethyl 
malonate under neutral conditions (90% yield).
49
 Afterwards, intermediates 64 a-c were 
converted in ethyl 2-(ethoxymethylene)propionate derivatives 65a-c by condensation 
with triethyl orthoformate in refluxing acetic anhydride. Compounds 65a-c were 
involved in an addition-elimination reaction with the proper amino alcohols in dry 
methylene chloride to yield the intermediates 66a–i. The oxazinoquinoline scaffold was 
obtained by cyclization using potassium carbonate (K2CO3) in dimethylformamide 
(DMF) at 130 °C. After saponification of ethyl ester derivatives 67a-i, the resulting 
carboxylic acids were coupled with the appropriate amines as reported in Scheme 3, to 
afford the target carboxamide derivatves. In the same way, reaction of compounds 65a-c 
with the proper (R)- or (S)-amino alcohol gave the corresponding enantiomerically pure 
derivatives, detailed in Table 5. 
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Scheme 5
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58-62 a: R1 = R2 = R4 = H, R5 = CH3
58-62 b: R1 = R2 = R4 = H, R5 = Phenyl
58-62 c: R1 = R2 = H, R4 = CH3, R5 = Phenyl
58-62 d: R1 = R2 = H, R4 = R5 = Phenyl
58-62 e: R1 = R4 = H, R2 = CH3, R5 = Phenyl
58-62 f: R1 = R2 = R4 = H, R5 = 4-Tolyl
58-62 g: R1 = R2 = R4 = H,  R5 = Cyclopropyl
58 h:     R1 = CH3, R2 = R4 = H,  R5 = Cyclopropyl
59-62 i: R1 =R2 = R4 = H, R5 = Propyl
59-62 j: R1 = CH3, R2 = R4 = H, R5 = Propyl
a Reagents and conditions: 
(i) -halo ketone, K2CO3, acetone (anhydrous), rt, 16 h; 
(ii) H2 (4 atm), 10% Pd/C, MeOH, 4 h; 
(iii) DEEM, 140 °C, 2 h; 
(iv) PPA, 140 °C, 1 h; 
(v) 10% NaOH, CH3OH, 80 °C, 1 h;
(vi) amine, EDC, HOBt, DMF, rt, 6 h or amine, DIEA, HBTU, DMF, rt, 16 h.
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Scheme 6
a
 
R2
F
F
R2
F
F
63-65 a: R1 = R2 = H
63-65 b: R2 = H, R3 = F
63-65 c: R1 = R2 = F
i iiOH
O
R3 R3
O
OEt
O
R2
F
FR3
O
OEt
O
OEt
63a-c 64a-c 65a-c
 
iii
N
O
R2
O
O
O
iv
R2
F
FR3
O
OEt
O
NH
HO R5
R6
R3
R5
R6
66a-i 67a-i  
 
 
 
v vi
N
O
R2
O
OH
O
R3
R5
R6
N
O
R2
O
N
H
O
R7
R3
R5
R6
68a-i (R)-81, (S)-81
(R)-83, (S)-83
84-91
101-104
108-109  
 
a:        R2 = R3 = H, R5, R6 = H, Methyl
b:        R2 = R3 = H, R5, R6 = H, Ethyl
c:        R2 = R3 = H, R5, R6 = H, i-Propyl
(R)-d: R2 = R3 = R6 = H, R5 = i-Butyl
e:        R2 = R3 = H, R5, R6 = H, Phenyl
(R)-f:  R2 = R3 = H, R5, R6 = H, Benzyl
g:        R2 = R3 = H, R5 = R6 =  CH3
h:        R2 = H, R3 = F, R5, R6 = H, Ethyl
i:         R2 = R3 = F, R5, R6 = H, Ethyl
a Reagents and conditions:
 (i) CDI, THF, (C2H5O)2Mg, monoethyl malonate, rt, 16 h; 
(ii) CH(OEt)3, Ac2O, 110 °C, 3 h; 
(iii) appropriate (R)-, (S)-, or (R,S)-amino alcohol, CH2Cl2, rt, 1 h; 
(iv) K2CO3, DMF, 130 °C, 7 h; 
(v) 10% NaOH, CH3OH, 80 °C, 1 h; 
(vi) amine, EDC, HOBt, DMF, rt, 6 h or amine, DIEA, HBTU, DMF, rt, 16 h.
 
 
Finally, the target compounds 105-107 were synthesized by substitution of the fluorine 
atom at C-10 by treating the amide 103 with different nucleophilic agents (sodium 
methoxide, pyrrolidine, N-methylpiperazine) in alkaline conditions (Scheme 7). 
Moreover, the 4-methylpiperazine derivative 107 was transformed into the 
hydrochloride salt by treatment with 1,4-dioxane saturated with gaseous hydrogen 
chloride. 
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Scheme 7
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aReagents and conditions: 
(i) CH3ONa, THF, 50 °C, 16 h; 
(ii) K2CO3, DMF, pyrrolidine, 100 °C, 10 h; 
(iii) K2CO3, DMF, 1-methylpiperazine, 100 °C, 10 h, then 1,4-dioxane saturated with HCl gas, 0 °C, 30 min.
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The newly synthesized compounds were tested in [
3
H]CP-55,940 competition binding 
experiments in order to value their affinity and selectivity towards the rat and human 
recombinant CB1 and CB2 receptors (Tables 2-5).  
Initially, it has been synthesized a series of 12 compounds (69–80, Table 2) bearing an 
aromatic moiety (phenyl or 4-tolyl) at C-3 of the oxazinoquinoline tricycle. Substituents 
on the carboxamide group at C-6 have been selected basing on known cannabinoid 
pharmacophores, such as those present in the naphthyridine
24, 45, 50
 (21) and quinolone
51-
53
 (22) derivatives. 
As expected, the 3-phenyl analogues bearing a cyclohexyl (70), cycloheptyl (71), 
adamant-1-yl (72), or 3,5-dimethyladamant-1-yl (73) carboxamide showed great affinity 
at the CB2 and poor affinity at the CB1 receptors. Compounds 71 and 73 were the most 
potent and selective in this group (71, h Ki = 0.81 nM, SI = 383; 73, hKi = 3.45 nM; SI = 
133). Compound 69, possessing a cyclopentyl carboxamide moiety, showed lower 
affinity and poor selectivity at the CB receptors, suggesting that the carboxamide group 
plays an important role, as reported in literature. 
Substitution of C-2 position with a methyl group resulted in a dramatic loss of affinity 
(74, hKi = 536 nM; 75, hKi = 332 nM), relative to that of the corresponding compounds 
lacking the methyl group (compounds 70 and 72, respectively). Likewise, compound 
76, which bears a phenyl group at C-2, was totally inactive at both CB receptors, 
confirming that the affinity of this class requires the C-2 position of the 
oxazinoquinoline nucleus unsubstituted. Intriguingly, the introduction of a methyl group 
at the para-position of the phenyl ring at C-3 (77, 78) provided a remarkable loss of 
affinity and selectivity for both CB receptors, in comparison with those of the analogous 
compounds 70 and 72 lacking this substituent. These data suggest that an excessive 
steric hindrance at this position prevents the receptor binding.  
It has been also investigated the substitution of C-9 of oxazinoquinoline scaffold, 
however the presence of a methyl group resulted in lower affinity (79, hKi =18.4 nM) 
and selectivity values, compared to those of the analogue without the methyl group (70). 
Derivative 80 was not tested due to its low solubility in DMSO/water. 
  
Table 2. Affinity (Ki, nM) and Selectivity Index (SI) of Novel 3-Aryl CB Compounds on Rat and Human CB1 
and CB2 Receptors and Potency (IC50, nM) of the Novel CB Compounds in hCB2 CHO Cells on cAMP 
Assays
a
 
N
O
O
N
H
O
R5
R7
R1
R2
R4
69-80  
      
Ki (nM)   
Cpd R1 R2 R4 R5 R7 rat CB1 rat CB2 hCB1 hCB2  SI 
hCB2 IC50
 
(nM)  
14 (R)-(+)-WIN 55,212-2 15.6 ± 1.4 7.58 ± 0.72 12.4 ± 1.3 4.53 ± 0.42 2.74 15.7 ± 1.3  
69 H H H Phenyl Cyclopentyl 150 ± 16 110 ± 12 132 ± 12 98 ± 10 1.35 472 ± 43  
70 H H H Phenyl Cyclohexyl 1150 ± 110 19.3 ± 2.3 420 ± 38 2.52 ± 0.21 166 15.2 ± 1.7  
71 H H H Phenyl Cycloheptyl 372 ± 36 14.7 ± 1.5 310 ± 29 0.81 ± 0.07 383 5.23 ± 0.42  
72 H H H Phenyl Adamant-1-yl 670 ± 65 18.3 ± 2.4 265 ± 24 14.2 ± 1.5 19 26 ± 3  
73 H H H Phenyl 
3,5-Dimethyl-
adamant-1-yl 
545 ± 53 46 ± 3 460 ± 48 3.45 ± 0.42 133 18.3 ± 1.9  
74 H H CH3 Phenyl Cyclohexyl 3520 ± 320 710 ± 44 3126 ± 288 536 ± 58 5.83 2749 ± 245  
75 H H CH3 Phenyl Adamant-1-yl 2640 ± 225 443 ± 26 2435 ± 231 332 ± 28 7.33 1684 ± 152  
76 H H Phenyl Phenyl Adamant-1-yl >10000 >10000 >10000 >10000 ND ND  
77 H H H 4-Tolyl Cyclohexyl 4566 ± 425 547 ± 32 4108 ± 380 468 ± 42 8.78 2457 ± 213  
78 H H H 4-Tolyl Adamant-1-yl 4154 ± 410 482 ± 43 3877 ± 362 412 ± 40 9.41 2215 ± 211  
79 H CH3 H Phenyl Cyclohexyl 1568 ± 164 25 ± 3 1346 ± 125 18.4 ± 1.9 73 110 ± 9  
80 H CH3 H Phenyl Adamant-1-yl ND ND ND ND ND 472 ± 43  
a
The data are expressed as the mean ± SEM of n = 4 independent experiments. 
b
The affinity values were calculated by using [
3
H]CP-55,940 as a 
radioligand on rat brain for CB1 receptors. 
c
The affinity values were calculated by using [
3
H]CP-55,940 as a radioligand on rat spleen for CB2 receptors. 
d
The affinity values were calculated by using [
3
H]CP-55,940 as a radioligand on human CB1 CHO membranes. 
e
The affinity values were calculated by 
using [
3
H]CP-55,940 as a radioligand on human CB2 CHO membranes. 
f
IC50 values were calculated on cAMP experiments performed on human CB2 
CHO cells.   
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The structure–activity relationship (SAR) studies were increased by synthesizing 3-
alkyl derivatives, in order to evaluate the effect of the chain length and branching 
(Table 3-4, compounds 81–101). Introduction of a methyl group at this position led to 
an enhancement in selectivity, although with a modest decrease in affinity. Derivatives 
81–83 each showed lower affinity for both CB receptors, compared to 3-phenyl 
analogues 70–72, although the selectivity for the type-2 CB receptor was improved with 
the cycloheptyl and adamant-1-yl amides (82 and 83, respectively). The introduction of 
two methyl residues at C-3 (compound 102) led to affinity levels comparable to that of 
analogue 83, while the selectivity was drastically reduced (Ki = 56 nM, SI = 4). The 
most representative compound of this group was 82 (hKi = 38 nM, SI > 263), bearing a 
cycloheptyl moiety on the carboxamide chain.  
Lengthening the aliphatic chain to an ethyl group (84–86) enhanced affinity for both 
receptors, despite an apparent loss in selectivity. Moving to 3-propyl derivatives (92-
95), further improvements in receptor affinity have been determined, without 
significantly changing selectivity, relative to those of the corresponding ethyl 
derivatives. Unfortunately, compound 93, bearing a cycloheptyl amide, was not tested 
due to its poor solubility in DMSO/water mixtures. Particularly, compound 92, with a 
cyclohexyl carboxamide, showed the greatest affinity for the CB2 receptor in this series, 
with an hKi = 0.32 nM. Substitution of n-propyl moiety at C-3 with a cyclopropyl (98–
100) or 2-propyl (101) group provided lower affinity compared to that of the analogous 
compounds with the n-propyl side chain. 
Basing on these data, we decided to extend the study within the 3-ethyl series, by 
introducing additional substituents on the heterocyclic nucleus, as a fluorine atom at the 
C-10 position (103): not only this modification did not significantly changed affinity at 
the CB2 receptor, relative to that of compound 86, but also the selectivity decreased 
about 1.5-fold. An additional fluorine group was introduced at C-9, but derivative 104 
turned out to be less active than the analogue 103 (hKi = 33 nM vs 7.34 nM) without 
affecting selectivity. In the same way, the introduction of a methyl residue at C-8 (96, 
97) in the 3-propyl series caused a remarkable reduction in CB2 receptor affinity and 
selectivity, relative to that of the corresponding compounds lacking the methyl moiety 
(92 and 94, respectively). Together, these data point out that modifications in this 
portion of the molecular core considerably condition the receptor binding. We decided 
to further explore this sensitivity introducing other substituents at C-10. 
 
  
Table 3. Affinity (Ki, nM) and Selectivity Index (SI) of the Novel 3-Alkyl CB Compounds on Rat 
and Human CB1 and CB2 Receptors and Potency (IC50, nM) of the Novel CB Compounds in hCB2 
CHO Cells on cAMP Assays
a
 
N
O
O
N
H
O
R7
81-92
R5
 
   
Ki (nM) 
  Cpd R5 R7 rat CB1
b
 rat CB2
c
 hCB1
d
 hCB2
e
 SI hCB2 IC50(nM)
f
 
14 (R)-(+)-WIN 55,212-2 15.6 ± 1.4 7.58 ± 0.72 12.4 ± 1.3 4.53 ± 0.42 2.74 15.7 ± 1.3 
81 CH3 cyclohexyl 2630 ± 254 65 ± 6 2150 ± 207 60 ± 8 36 245 ± 28 
82 CH3 cycloheptyl >10000 52 ± 3 >10000 38 ± 4 >263 210 ± 23 
83 CH3 adamant-1-yl >10000 55 ± 4 >10000 47 ± 4 >212 230 ± 22 
84 ethyl cyclohexyl 972 ± 83 24 ± 2 821 ± 78 22 ± 2 37 62 ± 7 
85 ethyl cycloheptyl 498 ± 52 11.4 ± 1.3 433 ± 42 9.24 ± 0.92 47 42 ± 3 
86 ethyl adamant-1-yl 725 ± 73 13.5 ± 1.5 689 ± 64 7.83 ± 0.82 88 38 ± 4 
87 propyl adamant-2-yl 425 ± 39 16.1 ± 1.5 389 ± 35 13.2 ± 1.2 30 57 ± 6 
88 propyl 5-methylhexan-2-yl >10000 196 ± 17 >10000 15.8 ± 1.4 >633 62 ± 6 
89 propyl pyridin-4-yl 1375 ± 112 183 ± 16 1150 ± 104 152 ± 14 8 683 ± 66 
90 propyl thiazol-2-yl 1622 ± 157 324 ± 28 1365 ± 115 265 ± 21 5 1127 ± 104 
91 propyl N,N-diisopropyl >10000 104 ± 10 >10000 85 ± 9 >118 423 ± 37 
92 propyl cyclohexyl 13.4 ± 1.5 1.84 ± 0.16 10.2 ± 0.9 0.32 ± 0.03 32 1.53 ± 0.16 
aThe data are expressed as the mean ± SEM of n = 4 independent experiments. bThe affinity values were calculated by using [3H]CP-55,940 as a 
radioligand on rat brain for CB1 receptors. 
cThe affinity values were calculated by using [3H]CP-55,940 as a radioligand on rat spleen for CB2 
receptors. dThe affinity values were calculated by using [3H]CP-55,940 as a radioligand on human CB1 CHO membranes. 
eThe affinity values were 
calculated by using [3H]CP-55,940 as a radioligand on human CB2 CHO membranes. 
fIC50 values were calculated on cAMP experiments performed on 
human CB2 CHO cells. 
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Compounds 105 and 107, bearing a methoxy and N-methylpiperazine group 
respectively, showed high affinity at the CB2 receptor, especially compound 105, 
suggesting that the two receptor subtypes present different steric tolerance at this 
position.  
The best results were obtained with compound 106, in which the 10-fluorine atom was 
displaced by a pyrrolidine residue, showing high affinity and exceptional selectivity at 
the CB2 receptor (hKi = 8.12, SI > 1231). The choice of these kind of substituents is due 
to the fact that tertiary amines can be converted into the correspondent hydrochloride 
salt, making this class of compounds water-soluble. This characteristic is more suitable 
for in vivo tests, as it will be described later in this work. 
Moreover, within the 3-ethyl series, we valued the effect of structural modifications at 
the 6-carboxamide side chain on receptor affinity and selectivity (compounds 84–91). 
As shown in the 3-aryl series, the cycloheptyl amide 85 displays higher affinity and 
selectivity for the CB2 receptor, rather than the cyclohexyl amide 84. On the other hand, 
the adamant-1-yl amide 86 shows affinity for the CB2 receptor quite similar to that of 
the cycloheptyl derivative, although with a remarkable increase in selectivity. Moving 
the point of attachment of the adamantane ring from the bridgehead 1-position (86) to 
the bridging 2-position (87) caused a moderate decrease in affinity and selectivity. 
Substitution of the aliphatic carbocyclic amide moieties with a heteroaromatic 4-pyridyl 
(89) or thiazol-2-yl (90) group resulted in a dramatic reduction of affinity and almost 
complete loss of selectivity for the type-2 receptor. Similarly, significant loss of affinity 
at the CB2 receptor was seen with the introduction of a bulky, noncyclic N,N-
diisopropyl amide moiety (91), although selectivity was slightly enhanced. In the 3-
ethyl series, best values were obtained with the 5-methylhexan-2-yl carboxamide chain 
(88, hKi = 15.8 nM, SI > 633). These data confirm the importance of 6-carboxamide 
group in receptor affinity and selectivity. 
 
  
Table 4. Affinity (Ki, nM) and Selectivity Index (SI) of the Novel 3-Alkyl CB Compounds on Rat and Human CB1 and CB2 
Receptors and Potency (IC50, nM) of the Novel CB Compounds in hCB2 CHO Cells on cAMP Assays 
a
 
 
N
O
O
N
H
O
R7
R1
R2
93-107
R3
R5
R6
 
        
Ki (nM)  
Cpd R1 R2 R3 R5 R6 R7 rat CB1
b
 rat CB2
c
 hCB1
d
 hCB2
e
 SI hCB2 IC50(nM)
f
 
14 (R)-(+)-WIN55,212–2 15.6 ± 1.4 7.58 ± 0.72 12.4 ± 1.3 4.53 ± 0.42 2.74 15.7 ± 1.3 
93 H H H Cyclopropyl H cycloheptyl ND ND ND ND ND ND 
94 H H H Cyclopropyl H adamant-1-yl 240 ± 25 2.73 ± 0.25 215 ± 20 2.34 ± 0.21 92 15.3 ± 1.4 
95 H H H Cyclopropyl H 3,5-dimethyladamant-1-yl 476 ± 44 10.7 ± 1.1 200 ± 23 3.62 ± 0.41 55 20 ± 3 
96 CH3 H H Isopropyl H cyclohexyl 874 ± 78 43 ± 4 756 ± 72 38 ± 4 20 122 ± 11 
100 H H H Ethyl H adamant-1-yl 482 ± 46 10.3 ± 1.2 389 ± 37 8.92 ± 0.91 44 32 ± 3 
101 H H H Ethyl H adamant-1-yl 366 ± 31 4.22 ± 0.38 323 ± 28 3.74 ± 0.32 86 12.4 ± 1.7 
102 H H H CH3 CH3 adamant-1-yl 276 ± 22 68 ± 6 221 ± 18 56 ± 5 4 242 ± 23 
103 H H F Ethyl H adamant-1-yl 452 ± 44 9.51 ± 0.88 389 ± 34 7.34 ± 0.68 53 27 ± 2 
104 H F F Ethyl H adamant-1-yl 1824 ± 176 37 ± 4 1752 ± 165 33 ± 3 53 145 ± 12 
105 H H OCH3 Ethyl H adamant-1-yl 589 ± 51 9.12 ± 0.86 521 ± 48 6.78 ± 0.62 77 24 ± 3 
106 H H pyrrolidin-1-yl Ethyl H adamant-1-yl >10000 10.5 ± 1.1 >10000 8.12 ± 0.83 >1231 29 ± 3 
107 H H 4-methylpiperazin-1-yl Ethyl H adamant-1-yl >10000 61 ± 5 >10000 42 ± 3 >238 196 ± 17 
aThe data are expressed as the mean ± SEM of n = 4 independent experiments. bThe affinity values were calculated by using [3H]CP-55,940 as a radioligand on rat brain for CB1 receptors. 
cThe affinity 
values were calculated by using [3H]CP-55,940 as a radioligand on rat spleen for CB2 receptors. 
dThe affinity values were calculated by using [3H]CP-55,940 as a radioligand on human CB1 CHO 
membranes. eThe affinity values were calculated by using [3H]CP-55,940 as a radioligand on human CB2 CHO membranes. 
fIC50 values were calculated on cAMP experiments performed on human 
CB2 CHO cells.
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Finally, given the presence of chiral carbon at C-3, we decided to evaluate the 
possibility of a difference between the two receptor subtypes in the stereofacial 
preference for substituents at this position. In order to achieve this goal, we prepared a 
set of compounds (81, 83, 85, 86, and 101) as single enantiomers in addition to the 
racemic mixtures (Table 5). With the C-3 methyl derivatives (81, 83), a stereochemical 
preference for the (R)-enantiomers over the corresponding (S)-enantiomers is observed. 
More important, the (R)-81 enantiomer (hKi = 24 nM, SI = 119) shows higher affinity 
for the CB2 receptor than the racemic mixture (hKi = 60 nM, SI = 36), but apparently 
poorer affinity for the type-1 receptor. As a result, (R)-81 also displays greater 
selectivity than the racemic mixture. Similarly, the (R)-enantiomer of compound 83 
displays greater affinity than the (S)-enantiomer, although the (R)-enantiomer does not 
significantly alter affinity or selectivity over the racemic compound. As for the 3-ethyl 
derivatives, the (R)-enantiomers of 85 and 86 both provided a 2-fold enhancement in 
affinity over the racemic compounds. At the same time, they also caused a 2-fold loss in 
selectivity for the CB2 receptor, with a consequent 4-fold improvement in affinity for 
the CB1 receptor. In contrast, the (S)-enantiomers of 85 and 86 caused a notable 
decrease in affinity for the CB2 receptor with almost complete loss of selectivity. 
Analogously, with the C-3 isopropyl derivative 101, the (R)-enantiomer turns out to 
have greater affinity to both CB receptors rather than the (S)-enantiomer or the racemic 
mixture ((R)-101, hCB1Ki = 88 nM; hCB2Ki = 1.24 nM; (S)-101, hCB1Ki = 858 nM; 
hCB2Ki = 16.2 nM; (R,S)-101, hCB1Ki = 323 nM; hCB2Ki = 3.74 nM). These data 
confirm a slight decrease in selectivity, relative to those of the racemic mixture. 
Basing on the fact that a significant enhancement in affinity and selectivity had been 
seen only with (R)-enantiomers, we continued SAR studies preparing just the 
enantiopure derivative. Acutally, we extended the side chain length, synthesizing 
compound (R)-108, which bears an isobutyl moiety at C-3. Indeed, this compound was 
found to bind to the CB2 receptor with high affinity and exceptional selectivity (hKi = 
9.24 nM, SI > 1082). In light of this finding, we also introduced a benzyl moiety at C-3, 
that led to the formation of compound (R)-109, in which a methylene spacer between 
the oxazine ring and the phenyl moiety of compound 72 has been placed. As expected, 
the compound showed higher affinity at the CB2 receptor, with a Ki of 3.72 nM, and a 
modest improvement in selectivity (SI = 28) relative to those of the C-3 phenyl 
analogue. 
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The novel 7-oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide derivatives were also 
examined in functional assays, in order to evaluate their potency. In particular, it has 
been analyzed the capability of the compounds to inhibit forskolin-induced cAMP 
production in hCB2 CHO cells (Tables 2-5). In Fig. 17 are reported competition binding 
curves (A) obtained from receptor binding experiments, and the dose-response curves 
(B) from cAMP assays for select compounds (92, 70, 71, (R)-86, and 105). We can see 
that high affinity values (Ki) are strictly correlated with high potency values (IC50). All 
the analysis were performed in comparison to the reference compound WIN55,212-2 
(14) that is characterized by high affinity and potency but very low selectivity (Tables 
2-5). These data reveal that modifications on the novel oxazinoquinolin-6-carboxamide 
scaffold do not affect its functionality, actually all compounds behave as full agonists. 
Interestingly, the affinity values obtained from rat and human receptors binding were 
quite similar, confirming a high degree of similarity between the two receptor subtypes 
across the two species. Consequently, these data support the evaluation of in vivo 
efficacy in rodent animal models of inflammatory and/or neuropathic pain.
34
 
 
 
 
 
92 Ki = 0.32 ± 0.03 nM 
71 Ki = 0.81 ± 0.07 nM 
70 Ki = 2.52 ± 0.21 nM 
(R)-86  Ki = 4.93 ± 0.45 nM 
105 Ki = 6.78 ± 0.62 nM  
 
 
 
 
92 IC50=  1.56  ± 0.16 nM 
71 IC50=  5.23  ± 0.42 nM 
70 IC50=  15.2  ± 1.6 nM 
(R)-86  IC50=  18.1  ± 1.7 nM 
105 IC50=  24  ± 3 nM 
 
 
 
 
 
 
Fig. 3. Affinity (Ki, nM) and potency (IC50, nM) of selected novel CB compounds:(A) competition curves 
on hCB2 receptors;(B) inhibition curves of forskolin-stimulated cAMP accumulation in hCB2 CHO cells. 
Results are given as the mean ± SEM (n = 4 independent experiments). 
 
 
  
 
Table 5. Affinity (Ki, nM) and Selectivity Index (SI) of the Novel Chiral CB Compounds on Rat and Human 
CB1 and CB2 Receptors and Potency (IC50, nM) of the Novel CB Compounds in hCB2 CHO Cells on cAMP 
Assays
a
 
 
N
O
O
N
H
O
R7
81, 83, 85, 86, 101, 108, 109
R5
R6
 
    
Ki (nM) 
  Cpd R5 R6 R7 rat CB1
b
 rat CB2
c
 hCB1
d
 hCB2
e
 SI hCB2 IC50(nM)
f
 
14 (R)-(+)-WIN55212-2 15.6 ± 1.4 7.58 ± 0.72 12.4 ± 1.3 4.53 ± 0.42 2.74 15.7 ± 1.3 
(R)-81 H CH3 cyclohexyl 3560 ± 335 30 ± 4 2866 ± 245 24 ± 3 119 90 ± 8 
(S)-81 CH3 H cyclohexyl 5242 ± 534 250 ± 27 4652 ± 425 188 ± 16 25 724 ± 75 
(R)-83 H CH3 adamant-1-yl >10000 52 ± 5 >10000 47 ± 3 >212 153 ± 14 
(S)-83 CH3 H adamant-1-yl >10000 86 ± 8 >10000 78 ± 7 >128 250 ± 23 
(R)-85 H Ethyl cycloheptyl 126 ± 11 6.03 ± 0.52 105 ± 9 4.12 ± 0.38 25 17.2 ± 1.6 
(S)-85 ethyl H cycloheptyl 913 ± 87 203 ± 19 843 ± 77 87 ± 16 4.05 682 ± 67 
(R)-86 H Ethyl adamant-1-yl 242 ± 21 6.17 ± 0.53 197 ± 15 4.93 ± 0.45 40 18.1 ± 1.7 
(S)-86 ethyl H adamant-1-yl 653 ± 58 97 ± 8 578 ± 44 88 ± 7 7 413 ± 38 
(R)-101 H Isopropyl adamant-1-yl 95 ± 9 1.75 ± 0.14 88 ± 7 1.24 ± 0.11 71 9.84 ± 0.91 
(S)-101 isopropyl H adamant-1-yl 864 ± 82 19.3 ± 1.9 858 ± 79 16.2 ± 1.8 53 55 ± 6 
(R)-108 H Isobutyl adamant-1-yl >10000 10.2 ± 1.1 >10000 9.24 ± 0.84 >1082 36 ± 3 
(R)-109 H Benzyl adamant-1-yl 121 ± 10 4.65 ± 0.43 105 ± 9 3.72 ± 0.32 28 17.5 ± 1.8 
aThe data are expressed as the mean ± SEM of n = 4 independent experiments. bThe affinity values were calculated by using [3H]CP-55,940 as a radioligand 
on rat brain for CB1 receptors. 
cThe affinity values were calculated by using [3H]CP-55,940 as a radioligand on rat spleen for CB2 receptors. 
dThe affinity 
values were calculated by using [3H]CP-55,940 as a radioligand on human CB1 CHO membranes. 
eThe affinity values were calculated by using [3H]CP-55,940 
as a radioligand on human CB2 CHO membranes. 
fIC50 values were calculated on cAMP experiments performed on human CB2 CHO cells. 
 47 
 
Antinociceptive effects of the 
selective CB2 agonist MT178 
5. Antinociceptive effects of the selective CB2 agonist MT178 
48 
Pain is an unpleasant feeling often caused by intense stimuli, that significantly affects 
the quality of life. Recent epidemiological studies reported that, in Italy, one out of 
every four patients suffers from chronic pain and that the available pharmacological 
treatments are barely effective.  
Evidence for the use of Cannabis extracts as analgesic treatment has been known 
forever. During the last decades, numerous studies have reported marked 
antinociceptive effects of CB agonists in various models of pain, both inflammatory and 
neuropathic,
54
 that could be very useful as tools to evaluate the therapeutic efficacy of 
novel potential analgesics.
55
  
Apparently, the inhibition of inflammatory and neuropathic persistent pain condition 
involves both CB1 and CB2 receptors. However, most drugs interacting with CB1 
receptors displayed marked side central effects that have precluded their application. As 
a consequence, it became necessary to develop new compounds that are selective for 
type-2 cannabinoid receptor.
56, 57
 
N-adamantyl-3-ethyl-3,7-dihydro-7-oxo-10-(pyrrolidin-1-yl)-2H-[1,4]oxazino[2,3,4-
ij]quinoline-6-carboxamide 106 is one of the most representative compounds in the 
newly developed series. It showed a high CB2 selectivity, making it suitable as an 
antinociceptive drug without CNS side effects. Moreover, the novel CB2 compound 
behaves as a potent full agonist, as indicated by cyclic AMP experiments performed in 
human CB2 receptors, with an EC50 value of 25.31 nM and an efficacy comparable to 
reference compound WIN 55,212-2 (Emax 99 ± 5 and 100 ± 6, respectively). 
The presence of a pyrrolidine residue at C-10 allowed the preparation of the 
correspondent hydrochloric salt, that made the compound water-soluble, and, 
consequently, suitable for in vivo tests, to better investigate the analgesic effect.  
 
O
N
O
N O
N
O
O O
N
H
N
WIN 55-212,2
h Ki CB2 = 4.53 nM
h IC50 CB2 = 15.7 nM
Emax = 100%
MT178
h Ki CB2 = 8.12 nM
h IC50 CB2 = 29 nM
Emax = 99%  
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Actually, labelled as MT178, compound 106 has been tested in two of the most used 
inflammatory pain models, such as formalin and writhing tests, where it produced a 
dose-dependent antihyperalgesic effect in a similar way to WIN55,212-2. Moreover, the 
effect of MT178 was reversed by the selective CB2 antagonist AM630, but not by the 
selective CB1 antagonist AM251, supporting a CB2-mediated mechanism of action, and 
the high selectivity.  
The effect of MT178 was also analyzed in different chronic pain models, that is to say 
streptozotocin (STZ)-induced neuropathy, bone cancer pain and acid-induced muscle 
pain (AIMP).
58
 In a very encouraging way, compound 106 significantly reduced 
mechanical allodinya in all the three models, with an efficacy comparable to that 
obtained with WIN55,212-2.  
Moreover, rotarod and catalepsy assays were performed to evaluate CNS adverse 
effects, and, as expected, WIN55,212-2 showed marked central side effects. On the 
other hand, the treatment with MT178 did not cause any locomotor disturbance or 
catalepsy, even at doses up to 100-fold the doses that caused antinociception.  
These results confirm that systemic administration of MT178 produces strong analgesia 
in different pain models through selective activation of CB2 receptors, providing an 
interesting approach to analgesic therapy in inflammatory and chronic pain without 
CB1-mediated central side effects. 
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This project focused on the design and synthesis of novel cannabinoid CB2 receptor 
ligands. Initially, the synthetic routes of three new scaffolds were optimized: 2,8- dioxo 
-1,2,3,4-tetrahydro-8H[1,4]diazepino[3,2,1-ij]quinoline-7-carboxamides, 8-oxo-1,2,3,4-
tetrahydro-8H[1,4]diazepino[3,2,1-ij]quinoline-7-carboxamides and 2,7-dioxo-2,3-
dihydro-1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides. These classes of 
compounds did not show encouraging results (KiCB2 > 150 nM).  
Consequent modification of the scaffold led to the discovery of a novel 7-oxo-
[1,4]oxazino[2,3,4-ij]quinoline carboxamide series. In particular, we obtained excellent 
CB2 receptor affinity, with Ki values less than 100 nM.  
Furthermore, considering the presence of a chiral center in position C-3, we evaluated 
the stereoselectivity of CB2 receptor, and data showed that the (R)-isomer provided 
higher affinity compared to the corresponding (S)-enantiomer. In particular, best results 
were obtained with compound (R)-108 (KiCB2 = 9.24 nM; SI > 1082).  
Moreover, the cAMP functional assays showed that the novel oxazinoquinoline series 
behaves as full agonist. 
Finally, one of the most selective compound, 106 (MT178), was analyzed in vivo both 
in inflammatory and neuropatic pain animal models and it revealed great efficacy as an 
antinociceptive agent. 
In conclusion, this work represents an interesting starting point for further optimization 
of CB2-receptor agonists as tools to study their therapeutic potential in various disease 
settings, especially pain. 
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Pharmacology 
Competition binding experiments were performed by using [
3
H]CP-55,940 (specific 
activity 180 Ci/mmol) that was obtained from Perkin-Elmer Life and Analytical 
Sciences (Waltham, MA). Human CB1 and CB2 receptors expressed in CHO cells were 
purchased from Perkin-Elmer Life and Analytical Sciences. All other reagents were of 
analytical grade and were obtained from commercial sources. 
 
Competition Binding Experiments on CB1 and CB2 Receptors 
 
To study CB1 receptors, rat brain (male Sprague-Dawley rats, Charles River, 
Wilmington, MA) was removed, frozen in liquid nitrogen, and stored at -80 °C. The rat 
brain tissue was suspended in 50 mM Tris-HCl buffer, pH 7.4, at 4 °C. The suspension 
was homogenized with a Polytron and centrifuged for 10 min at 2000g, and the 
supernatant was centrifuged again for 20 min at 40000g. The pellet was resuspended in 
a buffer containing 50 mM Tris-HCl, 1 mM EDTA, 3 mM MgCl2, and 0.5% fatty acid 
free bovine serum albumin (BSA), pH 7.4, at 30 °C. Competition binding experiments 
to rat CB1 receptors were carried out using [
3
H]CP-55,940 (1.0 nM), a membrane 
suspension containing 40 μg of protein/100 μL and different concentrations (1 nM to 10 
μM) of the examined compounds.  
To investigate CB2 receptors, a [
3
H]CP-55,940 binding assay was performed by using 
rat spleen (male Sprague–Dawley rats, Charles River) that was homogenized in 50 mM 
Tris-HCl buffer, pH 7.4, at 4 °C with a Polytron and centrifuged for 10 min at 2000g, 
and the supernatant was centrifuged for 20 min at 40000g. The pellet was resuspended 
in a buffer containing 50 mM Tris-HCl, 1 mM EDTA, 3 mM MgCl2, and 0.5% fatty 
acid free BSA, pH 7.4, at 30 °C. Competition binding experiments to rat CB2 receptors 
were performed using [
3
H]CP-55,940 (0.5 nM), a membrane suspension containing 80 
μg of protein/100 μL and different concentrations (1 nM to 10 μM) of the examined 
compounds.
59
  
Human CB1 and CB2 receptors expressed in CHO cells were grown adherently and 
maintained in Ham’s F12 containing 10% fetal bovine serum, penicillin (100 U/mL), 
streptomycin (100 μg/mL), and Geneticin (G418; 0.4 mg/mL) at 37 °C in 5% CO2/95% 
air.
60-62
 For membrane preparation the culture medium was removed, and the cells were 
washed with PBS and scraped off T75 flasks in ice-cold hypotonic buffer (5 mM Tris-
HCl, 2 mM EDTA, pH 7.4). The cell suspension was homogenized with a Polytron and 
centrifuged for 10 min at 1000g, and the supernatant was then centrifuged for 30 min at 
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100000g. The membrane pellet was suspended in 50 mM Tris-HCl buffer, 0.5% BSA 
(pH 7.4) containing 5 mM MgCl2, and 2.5 mM EDTA or 1 mM EDTA for hCB1 or 
hCB2 receptors, respectively. Competition binding experiments were performed using 
0.5 nM [
3
H]CP-55,940 and different concentrations (1 nM to 10 μM) of the examined 
compounds or the reference agonist WIN55,212-2 for an incubation time of 90 or 60 
min at 30 °C for CB1 or CB2 receptors, respectively. 
Bound and free radioactivities were separated by filtering the assay mixture through 
Whatman GF/C glass fiber filters using a Brandel cell harvester (Brandel Instruments, 
Unterföhring, Germany). The filter-bound radioactivity was counted using a Packard Tri 
Carb 2810 TR scintillation counter from Perkin-Elmer Life and Analytical Sciences. 
 
cAMP Assay to Human CB2 Receptors 
 
CHO cells transfected with human CB2 receptors were washed with phosphate-buffered 
saline and diluted trypsin and centrifuged for 10 min at 200g. The pellet containing 
CHO cells (1 × 10
6
 cells/assay) was suspended in 0.5 mL of an incubation mixture, 
NaCl (150 mM), KCl (2.7 mM), NaH2PO4 (0.37 mM), MgSO4 (1 mM), CaCl2 (1 mM), 
Hepes (5 mM), MgCl2 (10 mM), glucose (5 mM), pH 7.4, at 37 °C. Then 0.5 mM 4-(3-
butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 20-1724) as a phosphodiesterase 
inhibitor was added and preincubated for 10 min in a shaking bath at 37 °C.
63
 The 
potency of the novel CB compounds in comparison with a well-known CB agonist (14) 
was studied in the presence of forskolin (1 μM). The reaction was terminated by the 
addition of cold 6% trichloroacetic acid (TCA). The TCA suspension was centrifuged at 
2000g for 10 min at 4 °C, and the supernatant was extracted four times with water-
saturated diethyl ether. The final aqueous solution was tested for cAMP levels by a 
competition protein binding assay. Samples of cAMP standard (0-10 pmol) were added 
to each test tube containing the incubation buffer (Trizma base (0.1 M), aminophylline 
(8.0 mM), 2-mercaptoethanol (6.0 mM), pH 7.4) and [
3
H]cAMP in a total volume of 0.5 
mL. The binding protein previously prepared from beef adrenals was added to the 
samples previously incubated at 4 °C for 150 min, and after the addition of charcoal, the 
samples were centrifuged at 2000g for 10 min. The clear supernatant was counted by 
using a Perkin-Elmer 2810 TR scintillation counter (Perkin-Elmer Life and Analytical 
Sciences). The protein concentration was determined according to a Bio-Rad method 
(Bradford, 1976) with bovine albumin as a standard reference. Inhibitory binding 
constant values, Ki, were calculated from the IC50 according to the Cheng and Prusoff 
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equation.
64
 A weighted nonlinear least-squares curve fitting program, LIGAND,
65
 was 
used for computer analysis of inhibition experiments. All the data are expressed as the 
mean ± SEM of n = 4 independent experiments for the in vitro assays. Statistical 
analysis of the data was performed using unpaired two-sided Student’s t test. 
 
Chemistry 
 
Reagent grade solvents were dried according to standard techniques. Sodium sulphate 
was used as a drying agent for water containing organic phases. All reported yields are 
of isolated products and are not optimized. Reactions were routinely monitored by thin-
layer chromatography (TLC) on silica gel (F245 Merck plates). Chromatographic spots 
were visualized by UV light. Purification of crude compounds and separation of 
reaction mixtures were carried out by column chromatography on silica gel 60 (230–400 
mesh from Merck). Melting points (Mp) (uncorrected) were determined in a 240 Buchi-
Tottoli melting point apparatus. Chemical shifts (δ) are reported in parts per million 
(ppm) relative to the solvent central peak. 
1
H NMR spectra were recorded at 200 MHz 
or 400 MHz on a Bruker AC 200 spectrometer. Electron spray ionization mass 
spectrometry (ESI/MS) was performed with an Agilent 1100 Series LC/MSD model in 
positive scan mode. The molecular weights from the MS spectra were in full agreement 
with the proposed chemical structures of target compounds. Elemental analysis data for 
final compounds were obtained from the micro-analytical laboratory of Department of 
Chemistry, Ferrara University and were within ±0.40 of theoretical values for formulas 
given. Reagents and solvents were provided by Fluka-Aldrich, Sigma and Alfa-Aesar. 
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General Procedures 
 
Synthesis of 4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (32)
35
 
 
A mixture of 1,2-phenyldiamine (31, 0.018 mol) and 60% aqueous acrylic acid (0.027 
mol) dissolved in water (3.5 mL) and conc. hydrochloric acid (3.5 mL) was stirred at 
70°C for 3 h and monitored through TLC. The solvent was evaporated by distillation, 
basified with conc. ammonium hydroxide. The reaction mixture was partitioned 
between H2O and ethyl acetate (EtOAc). The organic layer was washed with brine, and 
dried over sodium sulfate (Na2SO4). The solvent was evaporated under reduced 
pressure. The desired product was crystallized from EtOAc. 
 
32 4,5-Dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one 
Pale white solid. Mp: 138 °C. Yield: 68%. MS m/z 163 (MH
+
). 
1
H NMR (200 MHz, 
DMSO):  7.99 (br s, 1 H); 7.02-6.70 (m, 4 H); 4.10 (br s, 1 H); 3.65 (m, 2 H); 2.72 (t, J 
= 5.4 Hz, 2 H).  
 
Synthesis of diethyl 2-[(1,2,3,4-tetrahydro-2-oxobenzo[b][1,4]diazepin-5-yl) 
methylene]malonate (33) 
 
A mixture of 4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (32, 0.005 mol) and 
Diethyl ethoxymetylenmalonate (DEEM) (0.005 mol) was heated at 140 °C for 1 h. The 
reaction mixture was poured into petroleum ether and the precipitate was collected by 
filtration to give the desired compound as a pale white solid (yield: 90%) that was 
filtered and used without any further purification in the next step. 
 
Synthesis of ethyl 2,3,4,8-tetrahydro-2,8-dioxo-1H-[1,4]diazepino[3,2,1-ij] 
quinoline-7-carboxylate (34) 
 
A mixture of diethyl 2-((1,2,3,4-tetrahydro-2-oxobenzo[b][1,4]diazepin-5-yl)methylene) 
malonate (33, 0.003 mol) and polyphosphoric acid (5 g) was heated at 130 °C for 1 h. 
The mixture was poured into ice and water to form a white precipitate that was filtered 
and washed with cold water to afford: 
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34 Ethyl 2,3,4,8-tetrahydro-2,8-dioxo-1H-[1,4]diazepino[3,2,1-ij]quinoline-7-
carboxylate 
White solid. Mp: 295 °C. Yield: 95%. MS m/z 287 (MH
+
), 
1
H NMR (200 MHz, 
DMSO):  10.11 (br s, 1 H); 8.53 (s, 1 H); 8.10-8.00 (m, 1 H); 7.50-7.25 (m, 2 H); 4.51 
(t, J = 4.6 Hz, 2 H); 4.23 (q, J = 7.2 Hz, 2 H); 2.96 (t, J = 4.8 Hz, 2 H); 1.28 (t, J = 7.2 
Hz, 3 H). 
13
C NMR (100 MHz, DMSO):  173.7, 172.2, 164.3, 150.2, 130.6, 130.1, 
129.0, 125.7, 124. 5, 121.5, 108.5, 59.7, 52.2, 36.4, 14.3.  
 
Synthesis of 2,3-dihydro-1H-benzo[b][1,4]diazepines (36)
36
 
 
A mixture of 1,2-phenylendiamine (31, 18.5 mmol), appropriate ketone (74 mmol) and 
N-Bromosuccinimide (1.85 mmol) was heated at 40 °C for 4 h and monitored by TLC 
(for compound 36a, the reaction mixture was stirred at 80 °C for 0.5 h, using p-
Toluensulfonic Acid as catalyst
66
 (1.85 mmol)). Reaction mixture was basified with 
NH3 to pH = 9 and then extracted with EtOAc. Organic layer was washed with brine, 
dried over Na2SO4, filtered and concentrated under vacuum. The desired products were 
purified on silica gel column, using a mixture of petroleum ether and EtOAc as eluent.
35
 
 
36a 2,3-Dihydro-2,2,4-trimethyl-1H-benzo[b][1,4]diazepine 
Pale yellow solid. Mp: 146-147 °C. Yield: 80%. MS m/z 189 (MH
+
). 
1
H NMR (200 
MHz, CDCl3):  7.10 (m, 1 H); 7.00-6.69 (m, 2 H); 6.75 (m, 1 H); 2.98 (br s, 1 H); 2.6 
(s, 3 H); 2.22 (s, 2 H); 1.34 (s, 6 H).  
36b 2,4-Diethyl-2,3-dihydro-2-methyl-1H-benzo[b][1,4]diazepine 
Yellow oil. Yield: 67%. MS m/z 217 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  7.15-7.10 
(m, 1 H); 6.97-6.92 (m, 2 H); 6.72-6.68 (m, 1 H); 3.01 (br s, 1 H); 2.63- 2.52 (q, J = 7.4 
Hz, 2 H); 2.25-2.19 (d, J = 12.6 Hz, 1 H); 2.15-2.08 (d, J = 12.6 Hz, 1 H); 1.65-1.61 (m, 
2 H); 1.27-1.19 (m, 6 H); 0.96-0.89 (t, J = 7.6 Hz, 3 H). 
36c 2,3,9,10a-Tetrahydro-1H-spiro[benzo[b]cyclopenta[e][1,4]diazepine-10,1'-
cyclopentane] 
Brown solid. Mp: 134-136 °C. Yield: 67%. MS m/z 241 (MH
+
). 
1
H NMR (200 MHz, 
CDCl3):  7.34-7.29 (m, 1 H); 6.98-6.93 (m, 1 H); 6.82-6.78 (m, 1 H); 6.59-6.54 (m, 1 
H); 3.99 (br s, 1 H); 2.77 (t, J = 6.8 Hz, 1, H); 2.16-1.54 (m, 14 H).  
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36d 2,3-Dihydro-2-methyl-2,4-diphenyl-1H-benzo[b][1,4]diazepine 
Yellow solid. Mp: 107-109 °C. Yield: 92%. MS m/z 313 (MH
+
). 
1
H NMR (200 MHz, 
CDCl3):  7.63-7.57 (m, 4 H); 7.31-7.20 (m, 7 H); 7.08-6.87 (m, 3 H); 3.52 (br s, 1 H); 
3.12-3.11 (d, J = 13 Hz, 1 H); 3.01-2.94 (d, J = 13 Hz, 1 H); 1.76 (s, 3 H). 
 
General synthetic procedure for of 2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine 
(38). 
 
A mixture of benzodiazepine (36, 0.02 mol), methanol (50 mL) and sodium borohydride 
(0.02 mol) was stirred at room temperature for 2 h and monitored by TLC (for 
compound 38c, the reaction mixture was stirred at 40 °C for 8 h). Methanol was 
evaporated under reduced pressure and the reaction mixture was partitioned between 
H2O and ethyl acetate (EtOAc). The organic layer was washed with brine, dried over 
Na2SO4 and concentrated in vacuum. The resulting product was purified on silica gel 
column, using a mixture of petroleum ether and EtOAc as eluent. 
 
38a 2,3,4,5-Tetrahydro-2,2,4-trimethyl-1H-benzo[b][1,4]diazepine 
Pale white solid. Mp: 60-61 °C. Yield: 80%. , MS m/z 191 (MH
+
). 
1
H NMR (200 MHz, 
CDCl3):  6.79-6.61 (m, 4 H); 3.26 (br s, 2 H); 3.22 (m, 1 H); 1.66-1.53 (m, 2 H); 1.32 
(s, 3 H); 1.22 (d, J = 6.4 Hz, 3 H); 1.08 (s, 3 H).  
38b 2,4-Diethyl-2,3,4,5-tetrahydro-2-methyl-1H-benzo[b][1,4]diazepine 
Yellow oil. Yield: 72 %. MS m/z 219 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  6.68-6.59 
(m, 4 H); 3.29 (br s, 2 H); 2.93 (m, 1 H); 1.66-1.52 (m, 6 H); 1.05-0.95 (m, 9 H).  
38c 2,3,3a,4,9,10a-Hexahydro-1H-spiro[benzo[b]cyclopenta[e][1,4]diazepine-10,1'-
cyclopentane] 
Pale yellow solid. Mp: 70 °C. Yield: 75%. MS m/z 243 (MH
+
). 
1
H NMR (200 MHz, 
CDCl3):  6.70- 6.61 (m, 4 H); 4.00 (br s, 2 H); 3.5 (m, 1 H); 2.7-1.2 (m, 15 H).  
38d 2,3,4,5-Tetrahydro-2-methyl-2,4-diphenyl-1H-benzo[b][1,4]diazepine 
Pale white solid. Mp: 132-133 °C. Yield: 80%. MS m/z 315 (MH
+
). 
1
H NMR (400 
MHz, CDCl3):  7.73 (m, 2 H); 7.46-7.25 (m, 8 H); 6.83 (m, 4 H); 4.22 (d d, J = 13 Hz, 
J = 12 Hz, 1 H); 3.83 (br s, 2 H); 2.44 (m, 1 H); 1.88 (d d, J = 13.6 Hz, J = 2 Hz, 1 H); 
1.64 (s, 3 H). 
13
C NMR (100 MHz, CDCl3):  150.3, 145.2, 139.7, 137.2, 128.8, 128.5, 
127.7, 127.0, 126.7, 125.3, 122.3, 120.6, 57.7, 57.2, 55.4, 23.7.  
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General synthetic procedure for diethyl 2-[(1,2,3,4-tetrahydro-2,2,4-
trimethylbenzo[b][1,4]diazepin-5-yl)methylene]malonate (39) 
 
Starting with 3,4,5-tetrahydro-2,2,4-trimethyl-1H-benzo[b][1,4]diazepines 38, the 
title compounds were prepared in a manner analogous to that described for 
compound 33 in 85-90% yields. Compounds 39a-d were used in the next step 
without purification. 
 
General synthetic procedure for ethyl 2,3,4,8-tetrahydro-8-oxo-1H-[1,4]diazepino 
[3,2,1-ij]quinoline-7-carboxylate (40) 
 
Starting with diethyl 2-((1,2,3,4-tetrahydro-2,2,4-trimethylbenzo[b][1,4]diazepin-5-
yl)methylene)malonates 39 a-d, the title compounds were prepared in a manner 
analogous to that described for compound 34. 
 
40a Ethyl 2,3,4,8-tetrahydro-2,2,4-trimethyl-8-oxo-1H-[1,4]diazepino[3,2,1-ij] 
quinoline-7-carboxylate 
Purification on silical gel column: EtOAc:petroleum ether 7/3. Yellow solid. Mp: 126 
°C. Yield: 40%. MS m/z 315 (MH
+
). 
1
H NMR (400 MHz, CDCl3):  8.52 (s, 1 H); 8.07 
(m, 1 H); 7.18 (m, 1 H); 6.91 (m, 1 H); 4.93 (m, 1 H); 4.39 (q, 2 H, J = 7.6 Hz); 3.46 (br 
s, 1H); 2.07 (d d, J = 14 Hz, J = 3.2 Hz, 1 H); 1.95 (m, 1 H); 1.41 (t, J = 7.2 Hz, 3 H); 
1.28 (s, 3 H); 1.16 (s, 3 H). 
13
C NMR (100 MHz, CDCl3):  174.1, 166.7,. 146.2, 138.0, 
125.8, 123.76, 120.1, 109.5, 60.8, 60.0, 54.7, 46.7, 32.0, 30.2, 21.5, 14.5.  
40b Ethyl 2,4-diethyl-2,3,4,8-tetrahydro-2-methyl-8-oxo-1H-[1,4]diazepino[3,2,1-ij] 
quinoline-7-carboxylate 
Purification on silical gel column: EtOAc:petroleum ether 6/4. Yellow solid. Mp: 135 
°C. Yield: 38%. MS m/z 343 (MH
+
). 
1
H NMR (400 MHz, CDCl3):  8.46 (s, 1 H); 8.05-
8.02 (d, J = 8 Hz, 1 H); 7.22-7.18 (t, J = 8 Hz, 1 H); 6.89-6.87 (d, J = 7.6 Hz, 1 H); 
4.57-4.48 (m, 1 H); 4.40-4.38 (q, J = 7.2 Hz, 2 H); 3.63 (br s, 1 H); 2.32-2.21 (m, 1 H); 
2.17-2.07 (m, 1 H); 1.97-1.94 (m, 2 H); 1.48-1.46 (q, J = 7.2 Hz, 2 H); 1.43-1.39 (t, J = 
7.2 Hz, 3 H); 1.16 (s, 3 H); 0.90-0.86 (t, J = 7.6 Hz, 3 H); 0.82-0.79 (t, J = 7.6 Hz, 3 H).  
40c Ethyl 3-oxo-9,10,11,11a-tetrahydro-3H,7H,8aH-spiro [cyclopenta[6,7] [1,4] 
diazepino[3,2,1-ij]quinoline-8,1'-cyclopentane]-2-carboxylate 
Purification on silica gel column: EtOAc:petroleum ether 1/1. Pale yellow solid. Mp: 
109 °C. Yield: 35%. MS m/z 367 (MH
+
). 
1
H NMR (400 MHz, CDCl3):  8.52 (s, 1 H); 
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7.96 (m, 1 H); 7.19 (m, 1 H); 6.80 (m, 1 H); 4.43 (m, 1 H); 4.39 (q, J = 7.2 Hz, 2 H); 
3.72 (br s, 1 H); 2.39 (m, 1 H); 2.04-1.58 (m, 14 H); 1.43 (t, J = 7.2 Hz, 3 H). 
40d Ethyl 2,3,4,8-tetrahydro-2-methyl-8-oxo-2,4-diphenyl-1H-[1,4]diazepino[3,2,1-ij] 
quinoline-7-carboxylate 
Purification on silica gel column: EtOAc:petroleum ether 8/2. Pale white solid. Mp: 150 
°C. Yield: 40%. MS m/z 439 (MH
+
). 
1
H NMR (400 MHz, CDCl3):  8.16 (m, 1 H); 8.11 
(s, 1 H); 7.29-7.11 (m, 11 H); 6.98 (m, 1 H); 5.99 (d d, J = 8.4 Hz, J = 1.6 Hz, 1 H); 
4.25 (q, J = 7.2 Hz, 2 H); 3.77 (br s, 1 H); 3.37 (d d, J = 15.2 Hz, J = 8.4 Hz, 1 H); 2.72 
(d d, J = 15.2 Hz, J = 2 Hz, 1 H); 1.64 (s, 3 H); 1.28 (t, J = 7.6 Hz).  
 
General synthetic procedure for 3,4-dihydroquinoxalin-2(1H)-one (32)
43
 
 
To a solution of appropriate 1,2-phenylendiamine (31, 27.8 mmol) in 
dimethylformamide (DMF) (30 mL) were added triethylamine (55.6 mmol) and 
ethyl 2-bromoacetate (30.5 mmol). The reaction was stirred at room temperature for 
16 h, and then heated at 80 °C for 3h. Solvent was removed under reduced pressure 
and the residue was poured into water and extracted with EtOAc. Organic layer was 
washed with aqueous saturated sodium bicarbonate solution and brine, dried over 
sodium sulfate, filtered and concentrated under vacuum. The desired products were 
purified on silica gel column.  
 
42a 3,4-Dihydroquinoxalin-2(1H)-one 
Purified on silica gel column (EtOAc:petroleum ether 1/1). Tan solid. Mp: 127-129 
°C. Yield: 55%. MS m/z 149 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  8.92 (br s, 1 H); 
7.20-6.93 (m, 4 H); 3.99 (s, 2 H); 3.40 (br s, 1 H). 
42b 6-Fluoro-3,4-dihydroquinoxalin-2(1H)-one 
Purified on silica gel column (EtOAc:petroleum ether 8/2). Tan solid. Mp: 245-246 
°C. Yield: 60%. MS m/z 167 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  10.32 (br s, 1 
H); 7.84 (m, 1 H); 7.21-7.05 (m, 2 H); 5.88 (br s, 1 H); 3.68 (s, 2 H).  
42c 6-Chloro-3,4-dihydroquinoxalin-2(1H)-one 
Purified on silica gel column (EtOAc-:petroleum ether 1/1). Tan solid. Mp: 214-215 
°C. Yield: 55%. MS m/z 183 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  10.00 (br s, 1 
H); 7.20 (m, 1 H); 7.05- 6.99 (m, 2 H); 5.80 (br s, 1 H); 3.65 (s, 2 H).  
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42d 3,4-Dihydro-6,7-dimethylquinoxalin-2(1H)-one 
Purified on silica gel column (EtOAc-:petroleum ether 1/1). Tan solid. Mp: 134-136 
°C. Yield: 48%. MS m/z 177 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  9.87 (br s, 1 H); 
7.10 (m, 1 H); 6.09 (m, 1 H); 5.72 (br s, 1 H); 3.72 (s, 2 H); 2.17 (m, 6 H). 
 
General synthetic procedure for diethyl 2-[(2,3-dihydro-2-oxoquinoxalin-4(1H)-yl) 
methylene]malonate (43) 
 
Starting with 3,4-dihydroquinoxalin-2(1H)-one 42a-d, the title compounds were 
prepared (70-75%) in a manner analogous to that described for compound 33. 
Compounds 43a-d were used in the next step without purification. 
 
General synthetic procedure for ethyl 1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-
de]quinoxaline-6-carboxylate (44) 
 
Starting with diethyl 2-((2,3-dihydro-2-oxoquinoxalin-4(1H)-yl)methylene) 
malonates 43a-d, the title compounds were prepared in a manner analogous to that 
described for compound 34. 
 
44a Ethyl 1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-carboxylate 
Purified on silica gel column (EtOAc:methanol 9/1). White solid. Mp >300 °C. 
Yield: 55%. MS m/z 273 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  11.16 (br s, 1 H); 
8.51 (s, 1 H); 7.71 (m, 1 H); 7.37-7.15 (m, 2 H); 5.01 (s, 2 H); 4.17 (q, J =7 Hz, 2 H); 
1.28 (t, J = 7 Hz, 3 H). 
13
C NMR (100 MHz, DMSO):  172.2, 164.3,. 162.2, 147.2, 
129.3, 127.6, 126.0, 125.2, 118.9, 116.6, 111.0, 59.8, 52.0, 14.3.  
44b Ethyl 9-fluoro-1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-
carboxylate 
Purified on silica gel column (EtOAc). White solid. Mp >300 °C. Yield: 50%. MS m/z 
291 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  11.18 (br s, 1 H); 8.55 (s, 1 H); 7.56-7.51 
(m, 1 H); 7.17-7.11 (m, 1 H); 5.02 (s, 2 H); 4.18 (q, J =7.22 Hz, 2 H); 1.27 (t, J = 7.4 
Hz, 3 H). 
16
F-NMR (397 MHz, DMSO):  = -114.094 (t, 1 F, J = 10 Hz, F-9). 
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44c Ethyl 9-chloro-1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-
carboxylate 
Purified on silica gel column (EtOAc). White solid. Mp: 292 °C.Yield: 50%. MS m/z 
307 (MH
+
). 
1
H NMR (200 MHz, CDCl3):  11.16 (br s, 1 H); 8.51 (s, 1 H); 7.71 (m, 1 
H); 7.13 (s, 1 H); 5.01 (s, 2 H); 4.18 (q, J =7.2 Hz, 2 H); 1.25 (t, J = 7.4 Hz, 3 H).  
44d Ethyl 1,2,3,7-tetrahydro-8,9-dimethyl-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-
carboxylate 
Purified on silica gel column (EtOAc). White solid. Mp: 271 °C.Yield: 50%. MS m/z 
301 (MH
+
). 
1
H NMR (200 MHz, DMSO-d6):  10.98 (br s, 1 H); 8.34 (s, 1 H); 6.98 (s, 
1 H); 4.92 s, 2 H); 4.22-4.18 (q, J = 7.2 Hz, 2 H); 2.64 (s, 3 H); 2.29-2.26 (m, 3 H); 
1.30-1.21 (t, J = 7 Hz, 3 H). 
 
Synthesic genereal procedures for Carboxylic Acid Derivatives (35, 41, 44) 
 
Starting products 34, 40a-d, 44a-d (0.5 mmol) were dissolved in acetic acid (15 mL) 
and aqueous solution of HCl 20% (6.5 mL) was added. The reaction was heated at 100 
°C for 4h and monitored by TLC. Solvent was evaporated under reduced pressure, and 
the residue was basified with an aqueous solution of NaOH 5% to pH = 6, to give a 
white precipitate that was filtered and washed with cold water.  
 
35 2,3,4,8-Tetrahydro-2,8-dioxo-1H-[1,4]diazepino[3,2,1-ij]quinoline-7-carboxylic 
acid 
White solid. Mp: 265-267 °C.Yield: 99%. MS m/z 255 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  15.12 (br s, 1 H); 10.32 (br s, 1 H); 8.93 (s, 1 H); 8.15-8.10 (d, J = 7.6 Hz, 
1 H); 7.71-7.54 (m, 2 H); 4.75-4.71 (m, 2 H); 3.08-3.04 (m, 2 H). 
41a 2,3,4,8-Tetrahydro-2,2,4-trimethyl-8-oxo-1H-[1,4]diazepino[3,2,1-ij]quinoline-7-
carboxylic acid 
White solid. Mp: 228 °C.Yield: 85%. MS m/z 287 (MH
+
). 
1
H NMR (200 MHz, DMSO-
d6):  15.2 (br s, 1 H); 8.77 (s, 1 H); 7.81-7.76 (m, 1 H);7.41-7.38 (m, 2 H); 5.73 (br s, 1 
H); 5.06 (m, 1 H); 2.11-2.04 (m, 2 H); 1.68-1.65 (m, 3 H); 1.19 (s, 3 H); 1.10 (s, 3 H). 
41b 2,4-Diethyl-2,3,4,8-tetrahydro-2-methyl-8-oxo-1H-[1,4]diazepino[3,2,1-ij] 
quinoline-7-carboxylic acid 
Pale yellow solid. Mp: 194 °C.Yield: 90%. MS m/z 315 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  15.35 (br s, 1 H); 8.86-8.82 (d, J = 7.4 Hz, 1 H); 7.79-7.74 (m, 1 H); 7.42-
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7.39 (m, 2 H); 5.86-5.79 (d, J = 15.2 Hz, 1 H); 4.79-4.61 (m, 1 H); 2.24-2.05 (m, 2 H); 
2.05-2.01 (m, 2 H); 1.42-1.36 (m, 2 H); 1.07 (s, 3 H); 0.78-0.66 (m, 6 H). 
41c 9,10,11,11a-Tetrahydro-3H,7H,8aH-spiro[cyclopenta[6,7][1,4]diazepino[3,2,1-ij] 
quinoline-8,1'-cyclopentane]-2-carboxylic acid 
Yellow solid. Mp:>300 °C.Yield: 72%. MS m/z 339 (MH
+
). 
1
H NMR (200 MHz, 
CDCl3):  15.01 (br s, 1 H); 8.76 (s, 1 H); 7.98-7.93 (d, J = 7.8 Hz, 1 H); 7.37-7.29 (t, J 
= 7.8 Hz, 1 H); 6.97-6.93 (d, J = 7.6 Hz, 1 H); 4.61-4.42 (m, 1 H); 3.95 (br s, 1 H); 2.57-
2.41 (m, 1 H); 2.09-1.25 (m, 14 H). 
41d 2,3,4,8-Tetrahydro-2-methyl-8-oxo-2,4-diphenyl-1H-[1,4]diazepino[3,2,1-ij] 
quinoline-7-carboxylic acid 
Yellow solid. Mp: 204 °C.Yield: 75%. MS m/z 402 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  14.9 (br s, 1 H); 8.10 (s, 1 H); 7.72-7.69 (m, 1 H); 7.58-7.35 (m, 10 H); 
7.13-7.05 (m, 3 H); 6.50 (m, 1 H); 3.71-3.57 (m, 1 H); 3.78-3.62 (m, 1 H); 1.56 (s, 3 H). 
45a 1,2,3,7-Tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-carboxylic acid 
White solid. Mp:>300 °C.Yield: 70%. MS m/z 245 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  15.18 (br s, 1 H); 11.35 (br s, 1 H); 8.90 (s, 1 H); 7.88-7.84 (d, J = 8 Hz, 1 
H); 7.52 (t, J= 8 Hz, 1 H); 7.34-7.30 (d, J = 7.4 Hz, 1 H); 5.18 (s, 2 H).  
45b 9-Fluoro-1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-carboxylic 
acid 
White solid. Mp:>300 °C.Yield: 99%. MS m/z 263 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  15.05 (br s, 1 H); 11.51 (br s, 1 H); 8.92 (s, 1 H); 7.56-7.51 (d d, J = 8.6 
Hz, 1 H); 7.17-7.11 (d d, J = 9.2 Hz, 1 H); 5.20 (s, 2 H). 
45c 9-Chloro-1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-carboxylic 
acid 
Brown solid. Mp:>300 °C.Yield: 68%. MS m/z 279 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  14.85 (br s, 1 H); 11.48 (br s, 1 H); 8.93 (s, 1 H); 7.79-7.78 (m, 1 H); 
7.27-7.26 (m, 1 H); 5.18 (s, 2 H). 
45d 1,2,3,7-Tetrahydro-8,9-dimethyl-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-
carboxylic acid 
White solid. Mp:>300 °C.Yield: 85%. MS m/z 273 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  15.65 (br s, 1 H); 11.18 (br s, 1 H); 8.80 (s, 1 H); 7.14 (s, 1 H); 5.12 (s, 2 
H); 2.76 (s, 3 H); 2.33 (s, 3 H). 
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Synthesis of N-adamantanylcarboxamide derivatives (46-48, 50-51, 53-56) 
 
To a stirred solution of the respective carboxylic acid (35, 41, 45, 0.2 mmol) in dry 
DMF (3 mL) was added diisopropylethylamine (DIPEA, 0.8 mmol). The resulting 
solution was stirred at room temperature for 10 min before addition of o-benzotriazol-1-
yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU, 0.3 mmol) and then 
stirred for another 3 h. 1-Aminoadamantane (0.3 mmol) was then added, and the 
solution was stirred for 16 h. DMF was evaporated under reduced pressure, and the 
residue was dissolved in ethyl acetate and successively washed with water-saturated 
sodium bicarbonate, water, and brine. The organic phase was dried over anhydrous 
sodium sulfate, evaporated, and finally purified by flash chromatography. 
 
46 N-Adamant-1-yl-2,3,4,8-tetrahydro-2,8-dioxo-1H-[1,4]diazepino[3,2,1-ij]quinoline-
7-carboxamide 
White solid. Mp: >300 °C. Yield: 45%. MS m/z 392 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  10.20 (br s, 1 H); 9.85 (br s, 1 H); 8.66 (s, 1 H); 8.11-8.07 (d d, J = 7.8 
Hz, 1 H); 7.58-7.53 (d d, J = 7.8 Hz, 1 H), 7.48-7.40 (t, J = 7.8 Hz, 1 H); 4.63-4.58 (m, 
2 H); 3.03-2.98 (m, 2 H); 1.98 (s, 9H); 1.67 (s, 6 H). 
47 N-Adamant-1-yl-2,3,4,8-tetrahydro-2,2,4-trimethyl-8-oxo-1H-[1,4]diazepino[3,2,1-
ij]quinoline-7-carboxamide 
White solid. Mp: 222 °C.Yield: 79%. MS m/z 420 (MH
+
). 
1
H NMR (200 MHz, DMSO-
d6):  9.98 (br s, 1 H); 8.67 (s, 1 H); 7.75-7.72 (m, 1 H); 7.26-7.24 (m, 2 H); 5.48 (br s, 
1 H); 4.99-4.85 (m, 1 H), 2.05-2.01 (m, 11 H); 1.66-1.61 (m, 9 H); 1.19 (s, 3 H); 1.08 (s, 
3 H). 
48 N-Adamant-1-yl-2,4-diethyl-2,3,4,8-tetrahydro-2-methyl-8-oxo-1H-[1,4]diazepino 
[3,2,1-ij]quinoline-7-carboxamide 
White solid. Mp: 215 °C.Yield: 50%. MS m/z 448 (MH
+
). 
1
H NMR (200 MHz, DMSO-
d6):  9.95 (br s, 1 H); 8.67 (s, 1 H); 7.74-7.65 (m, 1 H); 7.27-7.26 (m, 2 H); 5.62 (br s, 
1 H); 4.57-4.43 (m, 1H); 2.35-2.18 (m, 2 H); 2.05 (s, 9 H); 2.04-1.87 (m, 2 H); 1.66 (s, 
6 H); 1.40 (m, 2 H); 1.12 (s, 3 H); 0.73-0.65 (m, 6 H). 
50 N-Adamant-1-yl-9,10,11,11a-tetrahydro-3H,7H,8aH-spiro[cyclopenta[6,7][1,4] 
diazepino[3,2,1-ij]quinoline-8,1'-cyclopentane]-2-carboxamide 
Pale yellow solid. Mp:>300 °C.Yield: 45%. MS m/z 472 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  9.91 (br s, 1 H); 8.74 (s, 1 H); 7.63-7.58 (d d, J = 7.6 Hz, 1 H); 7.23-7.16 
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(m, 2 H); 5.96 (br s, 1 H); 4.73-4.67 (m, 1 H); 2.46-2.38 (m, 1 H); 1.98 (m, 9 H); 1.96-
1.38 (m, 20 H). 
51 N-Adamant-1-yl-2,3,4,8-tetrahydro-2-methyl-8-oxo-2,4-diphenyl-1H-[1,4]diazepino 
[3,2,1-ij]quinoline-7-carboxylic acid 
White solid. Mp: 293 °C.Yield: 45%. MS m/z 402 (MH
+
). 
1
H NMR (200 MHz, DMSO-
d6):  9.81 (br s, 1 H); 8.12 (s, 1 H); 7.74-7.68 (m, 1 H); 7.46-7.25 (m, 9 H); 7.12-7.08 
(m, 3 H); 6.41-6.37 (m, 1 H); 6.18 (br s, 1H); 3.61-3.42 (m, 1 H); 2.67-2.58 (m, 1 H); 
1.93 (s, 9 H); 1.61 (s, 6 H); 1.53 (s, 3 H). 
53 N-Adamant-1-yl-1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-6-
carboxamide 
White solid. Mp:>300 °C.Yield: 50%. MS m/z 378 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  11.22 (br s, 1 H); 9.91 (br s, 1 H); 8.63 (s 1 H); 7.83-7.78 (d d, J = 8.4 Hz, 
1 H); 7.41-7.34 (t, J = 7.6 Hz, 1 H); 7.23-7.18 (d d, J = 7.6 Hz, 1 H); 5.10 (br s, 2 H); 
2.06 (s, 9 H); 1.67 (s, 6 H). 
54 N-Adamant-1-yl-9-fluoro-1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-
6-carboxamide 
White solid. Mp:>300 °C.Yield: 45%. MS m/z 397 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  11.34 (br s, 1 H); 9.83 (br s, 1H); 8.64 (s, 1 H); 7.48-7.42 (d d, J = 9.2 Hz, 
1 H); 7.05-6.99 (d d, J = 9 Hz, 1 H); 5.12 (br s, 2 H); 1.99 (s, 9 H); 1.67 (s, 6 H). 
55 N-Adamant-1-yl-9-chloro-1,2,3,7-tetrahydro-2,7-dioxopyrido[1,2,3-de]quinoxaline-
6-carboxamide 
Pale orange solid. Mp:>300 °C.Yield: 48%. MS m/z 412 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  11.17 (br s, 1 H); 9.78 (br s, 1 H); 8.65 (s, 1 H); 7.73-7.70 (m, 1 H); 7.17-
7.16 (m, 1 H); 5.11 (s, 2 H); 2.06 (s, 9 H); 1.67 (s, 6 H). 
56 N-Adamant-1-yl-1,2,3,7-tetrahydro-8,9-dimethyl-2,7-dioxopyrido[1,2,3-de] 
quinoxaline-6-carboxamide 
White solid. Mp:>300 °C.Yield: 55%. MS m/z 407 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  11.02 (br s, 1 H); 9.97 (br s, 1 H); 8.51 (s, 1 H); 7.02 (s, 1 H); 5.02 (s, 2 
H); 2.71 (s, 3 H); 2.29 (s, 3 H); 2.05 (s, 9 H); 1.67 (s, 6 H). 
 
Synthesis of N-cyclohexylcarboxamide derivatives (49, 52) 
 
To a solution of the appropriate carboxylic acid (41b, 41d, 0.6 mmol) in DMF (5 mL) 
were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 0.6 mmol), 1-
hydroxybenzotriazole (HOBt, 0.6 mmol), and finally cyclohexylamine (0.9 mmol). The 
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reaction mixture was stirred at room temperature for 6 h. The solvent was evaporated, 
and the residue was purified by column chromatography to yield a white solid. 
 
49 N-Cyclohexyl-2,4-diethyl-2,3,4,8-tetrahydro-2-methyl-8-oxo-1H-[1,4] diazepino 
[3,2,1-ij]quinoline-7-carboxamide 
White solid. Mp: 191 ° C. Yield: 48%. MS m/z 273 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  10.01 (br d, J = 7.8 Hz, 1 H); 8.71 (s, 1 H); 7.77-7.68 (m, 1 H); 7.28-7.26 
(m, 2 H); 5.62 (s, 1 H); 4.55-4.45 (m, 1 H); 3.82-3.74 (m, 1 H); 2.35-1.31 (m, 10 H); 
1.30-1.05 (m, 10 H); 0.71-0.68 (m, 5 H). 
52 N-Cyclohexyl-2,3,4,8-tetrahydro-2-methyl-8-oxo-2,4-diphenyl-1H-[1,4]diazepino 
[3,2,1-ij]quinoline-7-carboxamide 
White solid. Mp: 278 ° C. Yield: 45%. MS m/z 492 (MH
+
). 
1
H NMR (200 MHz, 
DMSO-d6):  9.90-9.86 (d, J = 8 Hz, 1 H); 8.13 (s, 1 H); 7.73-7.69 (d d, J = 7.8 Hz, 1 
H); 7.44-7.01 (m, 12 H); 6.37-6.33 (d, J = 8 Hz, 1 H); 6.19 (br s, 1 H); 3.63-3.51 (m, 1 
H); 2.62-2.58 (m, 1 H); 1.78-1.18 (m, 14 H). 
 
Synthesis of 2-Nitrophenoxy Ketones (58a-h) 
 
To a solution of 2-nitrophenol (57a-c, 14 mmol) in anhydrous acetone (10 mL) were 
added K2CO3 (15 mmol) and the appropriate halo ketone (1.1 eq). After being stirred 
vigorously at room temperature until the starting material disappeared as determined by 
TLC, the reaction mixture was filtered and the filtrate evaporated under reduced 
pressure. The residue was dissolved in ethyl acetate (150 mL) and washed with water 
(30 mL). The organic layer was dried over sodium sulfate and concentrated under 
vacuum. The residue was purified by column chromatography using ethyl 
acetate/petroleum ether as the eluent or by crystallization to yield the desired 
compound. 
 
58a 1-(2-Nitrophenoxy)propan-2-one  
White solid. Mp: 72 °C. Yield: 72%. MS: m/z 196.0 (M + H). 
1
H NMR (DMSO-d6): δ 
7.91–7.86 (m, 1H), 7.61–7.57 (m, 1H), 7.24–7.13 (m, 2H), 5.05 (s, 2H), 2.17 (s, 3H). 
58b 2-(2-Nitrophenoxy)-1-phenylethanone  
Yellow solid. Mp: 116–117 °C. Yield: 71%. MS: m/z 258.2 (M + H). 1H NMR (CDCl3): 
δ 8.03–7.98 (m, 2H), 7.90–7.85 (m, 1H), 7.61–7.45 (m, 4H), 7.11–6.95 (m, 2H), 5.45 (s, 
2H). 
7. Experimental Section 
67 
58c 2-(2-Nitrophenoxy)-1-phenylpropan-1-one  
Yellow oil. Yield: 69%. MS: m/z 272.4 (M + H). 
1
H NMR (DMSO-d6): δ 8.08–8.04 (m, 
2H), 7.89–7.85 (m, 1H), 7.72–7.59 (m, 3H), 7.15–7.11 (m, 2H), 6.29 (q, J = 6.8 Hz, 
1H), 1.57 (d, J = 6.6 Hz, 3H). 
58d 2-(2-Nitrophenoxy)-1,2-diphenylethanone  
Yellow solid. Mp: 58 °C. Yield: 15%. MS: m/z 334.3 (M + H). 
1
H NMR (DMSO-d6): δ 
8.08–7.86 (m, 2H), 7.30–7.54 (m, 5H), 7.03–7.19 (m, 7H), 6.48 (s, 1H). 
58e 2-(5-Methyl-2-nitrophenoxy)-1-phenylethanone  
Yellow solid. Mp: 132–134 °C. Yield: 75%. MS: m/z 272.1 (M + H). 1H NMR (CDCl3): 
δ 8.03–7.99 (m, 2H), 7.83–7.54 (m, 4H), 7.16 (s, 1H), 6.96–6.91 (m, 1H), 5.83 (s, 2H), 
2.32 (s, 3H). 
58f 1-(4-Methylphenyl)-2-(2-nitrophenoxy)ethanone  
White solid. Mp: 125 °C. Yield: 73%. MS: m/z 272.8 (M + H). 
1
H NMR (DMSO-d6): δ 
7.92–7.86 (m, 3H), 7.58–7.53 (m, 1H), 7.40–7.36 (m, 2H), 7.28–7.23 (m, 1H), 7.16–
7.11 (m, 1H), 5.81 (s, 2H), 2.40 (s, 3H). 
58g 1-Cyclopropyl-2-(2-nitrophenoxy)ethanone  
White solid. Mp: 58 °C. Yield: 75%. MS: m/z 222.1 (M + H). 
1
H NMR (DMSO-d6): δ 
7.91–7.86 (m, 1H), 7.61–7.57 (m, 1H), 7.20–7.13 (m, 2H), 5.21 (s, 2H), 2.22 (m, 1H), 
1.01–0.90 (m, 4H). 
58h 1-Cyclopropyl-2-(4-methyl-2-nitrophenoxy)ethanone  
Brown oil. Yield: 69%. MS: m/z 236.2 (M + H). 
1
H NMR (DMSO-d6): δ 7.89 (m, 1H), 
7.19–7.12 (m, 2H), 5.20 (s, 2H), 2.32 (s, 3H), 2.21 (m, 1H), 1.01–0.90 (m, 4H). 
 
Synthesis of Benzo[1,4]oxazines (59a–g,i,j) 
 
To a solution of the nitro ketone 58a–h (7 mmol) in methanol (100 mL) (in the case of 
3-aryl in methanol/THF, 85:15) was added 10% palladium on carbon (0.3 mmol), and 
the mixture was shaken under 4 atm of hydrogen at room temperature for 6 h. The 
reaction was monitored by TLC, and when complete, the suspension was filtered 
through a pad of Celite to remove the catalyst. The filtrate was concentrated under 
vacuum to give a yellow residue that was purified by column chromatography using 
ethyl acetate/petroleum ether (0.5/9.5) to yield the desired compounds. The cyclopropyl 
derivative 59g and propyl derivative 59i were separated by column chromatography 
using ethyl acetate/petroleum ether (0.2/9.8) as the eluent. 
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59a 3,4-Dihydro-3-methyl-2H-benzo[b][1,4]oxazine  
Colorless oil. Yield: 80%. MS: m/z 150.1 (M + H). 
1
H NMR (DMSO-d6): δ 6.68–6.40 
(m, 4H), 5.72 (br s, 1H), 4.15–4.07 (m, 1H), 3.65–3.56 (m, 1H), 3.37–3.36 (m, 1H), 
1.07 (d, J = 6.4 Hz, 3H). 
59b 3,4-Dihydro-3-phenyl-2H-benzo[b][1,4]oxazine  
White solid. Mp: 40 °C. Yield: 76%. MS: m/z 212.2 (M + H). 
1
H NMR (DMSO-d6): δ 
7.43–7.37 (m, 5H), 6.85–6.67 (m, 4H), 5.99 (br s, 1H); 4.53–4.49 (m, 1H),4.34–4.27 
(m, 1H), 4.06–3.95 (m, 1H). 
59c 3,4-Dihydro-2-methyl-3-phenyl-2H-benzo[b][1,4]oxazine  
Pale yellow oil. Yield: 83%. MS: m/z 226.0 (M + H). 
1
H NMR (DMSO-d6): δ 7.34–7.30 
(m, 5H), 6.74–6.69 (m, 3H), 6.58–6.43 (m, 1H), 6.38 (br s, 1H), 4.47-.4.44 (m, 2H), 
0.98 (d, J = 6.4 Hz, 3H). 
59d 3,4-Dihydro-2,3-diphenyl-2H-benzo[b][1,4]oxazine  
Orange solid. Mp: 161–162 °C dec. Yield: 71%. MS: m/z 288.8 (M + H). 1H NMR 
(CDCl3): δ 7.18–7.13 (m, 7H), 6.99–6.75 (m, 8H), 5.44 (d, J = 3.2 Hz, 1H), 4.70 (d, J = 
3 Hz, 1H). 
59e 3,4-Dihydro-7-methyl-3-phenyl-2H-benzo[b][1,4]oxazine  
White solid. Mp: 88 °C. Yield: 77%. MS: m/z 226.3 (M + H). 
1
H NMR (DMSO-d6): δ 
7.41–7.33 (m, 5H), 6.62–6.50 (m, 3H), 6.03 (br s, 1H), 4.48 (m, 1H), 4.17 (m, 1H), 
3.91–3.82 (m, 1H), 2.13 (s, 3H). 
59f 3,4-Dihydro-3-(4-methylphenyl)-2H-benzo[b][1,4]oxazine  
Colorless oil. Yield: 83%. MS: m/z 226.1 (M + H). 
1
H NMR (DMSO-d6): δ 7.29 (dd, J 
= 8 Hz, 2H), 7.17 (dd, J = 8 Hz, 2H), 6.71–6.66 (m, 3H), 6.54–6.48 (m, 1H), 6.20 (br s, 
1H), 4.39 (m, 1H), 4.21–4.14 (m, 2H), 3.89–3.80 (m, 1H), 2.30 (s, 3H). 
59g 3,4-Dihydro-3-cyclopropyl-2H-benzo[b][1,4]oxazine  
Yellow oil. Yield: 38%. MS: m/z 176.5 (M + H). 
1
H NMR (DMSO-d6): δ 6.65–6.59 (m, 
3H), 6.45–6.41 (m, 1H), 5.80 (br s, 1H), 4.19–4.15 (m, 1H), 3.56–3.81 (m, 1H), 2.58–
2.57 (m, 1H), 0.78–0.76 (m, 1H) 0.48–0.32 (m, 4H). 
59i 3,4-Dihydro-3-propyl-2H-benzo[b][1,4]oxazine  
Yellow oil. Yield: 54%. MS: m/z 178.4 (M + H). 
1
H NMR (DMSO-d6): δ 6.66–6.58 (m, 
3H), 6.46–6.42 (m, 1H), 5.71 (br s, 1H), 4.14–4.10 (m, 1H), 3.72–3.67 (m, 1H), 3.25–
3.24 (m, 1H), 1.41–1.37 (m, 4H), 0.91 (t, J = 6.8 Hz, 3H). 
  
7. Experimental Section 
69 
59j 3,4-Dihydro-6-methyl-3-propyl-2H-benzo[b][1,4]oxazine  
Yellow oil. Yield: 81%. MS: m/z 192.3 (M + H). 
1
H NMR (CDCl3): δ 6.68 (m, 1H), 
6.48–6.42 (m, 2H), 4.22–4.16 (m, 1H), 3.86–3.77 (m, 1H), 3.67 (br s, 1H), 3.40–3.35 
(m, 1H), 2.21 (s, 3H), 1.49–1.41 (m, 4H), 1.01–0.94 (m, 3H). 
 
Synthesis of Diethyl 2-[(2,3-Dihydro-2/3-substituted-benzo[b][1,4]oxazin-4-yl) 
methylene]malonate derivatives (60a–g,i,j) 
 
A mixture of benzo[1,4]oxazine 59a–g,i,j (4.7 mmol) and diethyl (ethoxymethylene) 
malonate (4.7 mmol) was heated with stirring at 140 °C for 2 h. The solvent was 
removed under reduced pressure, and cold diethyl ether was added to form a precipitate 
that was filtered and subsequently purified by column chromatography using ethyl 
acetate/petroleum ether (0.5/9.5). 
 
60a Diethyl 2-((2,3-Dihydro-3-methylbenzo[b][1,4]oxazin-4-yl)methylene)malonate  
Pale yellow oil. Yield: 73%. MS: m/z 320.1 (M + H). 
1
H NMR (DMSO-d6): δ 7.71 (s, 
1H), 7.21–6.95 (m, 4H), 4.21–3.87 (m, 7H), 1.26–1.16 (m, 9H). 
60b Diethyl 2-((2,3-Dihydro-3-phenylbenzo[b][1,4]oxazin-4-yl)methylene)malonate  
White solid. Mp: 103–104 °C. Yield: 81%. MS: m/z 382.2 (M + H). 1H NMR (CDCl3): 
δ 8.12 (s, 1H) 7.38–6.87 (m, 9H), 4.55–3.93 (m, 6H) 3.42–3.21 (m, 1H), 1.26 (t, J = 7 
Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H). 
60c Diethyl 2-((2,3-Dihydro-2-methyl-3-phenylbenzo[b][1,4]oxazin-4-yl)methylene) 
malonate  
White solid. Mp: 130 °C. Yield: 89%. MS: m/z 396.2 (M + H). 
1
H NMR (DMSO-d6): δ 
7.85 (s, 1H), 7.33–7.27 (m, 4H), 7.10–6.93 (m, 5H), 5.02 (d, J = 2.6 Hz, 1H), 4.60–4.43 
(m, 1H), 4.11–3.95 (m, 3H), 3.64–3.61 (m, 1H), 1.20–1.13 (m, 6H), 0.93 (t, J = 7.2 Hz, 
3H). 
60d Diethyl 2-((2,3-Dihydro-2,3-diphenylbenzo[b][1,4]oxazin-4-yl)methylene)malonate  
White solid. Mp: 114 °C. Yield: 96%. MS: m/z 458.2 (M + H). 
1
H NMR (DMSO-d6): δ 
7.96 (s, 1H), 7.42–7.30 (m, 4H), 7.18–7.04 (m, 8H), 6.43–6.40 (m, 2H), 5.69 (d, J = 2.6 
Hz, 1H), 5.34 (d, J = 2.8 Hz, 1H), 4.14–4.10 (m, 2H), 3.98–3.81 (m, 1H), 3.56–3.41 (m, 
1H), 1.18 (t, J = 7.2 Hz, 3H), 0.87 (t, J = 7.2 Hz, 3H). 
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60e Diethyl 2-((2,3-Dihydro-7-methyl-3-phenylbenzo[b][1,4]oxazin-4-yl)methylene) 
malonate  
White solid. Mp: 105 °C. Yield: 92%. MS: m/z 396.2 (M + H). 
1
H NMR (DMSO-d6): δ 
7.93 (s, 1H), 7.30–7.15 (m, 6H), 6.87–6.82 (m, 1H), 6.64–6.63 (m, 1H), 5.14 (m, 1H), 
4.72–4.65 (m, 1H), 4.36–4.29 (m, 1H), 4.11 (q, J = 6.2 Hz, 2H), 3.88–3.79 (m, 1H), 
3.32–3.23 (m, 1H), 2.20 (s, 3H), 1.17 (t, J = 7 Hz, 3H), 0.77 (t, J = 7 Hz, 3H). 
60f Diethyl 2-((2,3-Dihydro-3-(4-methylphenyl)benzo[b][1,4]oxazin-4-yl)methylene) 
malonate  
White solid. Mp: 94 °C. Yield: 87%. MS: m/z 396.2 (M + H). 
1
H NMR (DMSO-d6): δ 
7.94 (s, 1H), 7.33 (m, 1H), 7.08–6.99 (m, 6H), 6.83–6.78 (m, 1H), 5.13 (m, 1H), 4.78–
4.62 (m, 1H), 4.38–4.31 (m, 1H), 4.11 (q, J = 6.2 Hz, 2H), 3.97–3.78 (m, 1H), 3.42–
3.21 (m, 1H), 2.23 (s, 3H), 1.82 (t, J = 7.4 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H). 
60g Diethyl 2-((3-Cyclopropyl-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)methylene) 
malonate 
Yellow oil. Yield: 92%. MS: m/z 346.1 (M + H). 
1
H NMR (DMSO-d6): δ 7.72 (s, 1H), 
7.12–6.90 (m, 4H), 4.36–4.35 (m, 1H), 4.20–4.05 (m, 3H), 3.97–3.65 (m, 2H), 3.51–
3.47 (m, 1H), 1.19 (t, J = 7 Hz, 3H), 1.06 (t, J = 7 Hz, 3H), 0.98–0.83 (m, 2H), 0.53–
0.43 (m, 3H). 
60i Diethyl 2-((2,3-Dihydro-3-propylbenzo[b][1,4]oxazin-4-yl)methylene)malonate  
Yellow oil. Yield: 84%. MS: m/z 348.2 (M + H). 
1
H NMR (DMSO-d6): δ 7.70 (s, 1H), 
7.14–6.89 (m, 4H), 4.35 (m, 1H), 4.17–3.78 (m, 6H), 1.48–1.05 (m, 10H), 0.85 (t, J = 
7.4 Hz, 3H). 
60j Diethyl 2-(2,3-Dihydro-6-methyl-3-propylbenzo[b][1,4]oxazin-4-yl)methylene) 
malonate  
Yellow oil. Yield: 78%. MS: m/z 362.3 (M + H). 
1
H NMR (DMSO-d6): δ 7.84 (s, 1H), 
6.88–6.78 (m, 3H), 4.30–4.07 (m, 6H), 3.82 (m, 1H), 2.27 (s, 3H), 1.63–1.59 (m, 4H), 
1.32–1.22 (m, 6H), 0.92 (t, J = 7 Hz, 3H). 
 
Synthesis of Ethyl 3,7-Dihydro-2/3-substituted-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxylates (61a–g,i,j) 
 
A mixture of diethyl ester 60a–g,i,j (1.5 mmol) and poly(phosphoric acid) (3 g) was 
heated at 140 °C for 1 h. The mixture was poured into ice and water to form a 
precipitate that was filtered and washed with cold water. 
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61a Ethyl 3,7-Dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 189 °C dec. Yield: 95%. MS: m/z 274.3 (M + H). 
1
H NMR (DMSO-
d6): δ 8.65 (s, 1H), 7.80–7.75 (m, 1H), 7.40–7.31 (m, 2H), 4.79–4.63 (m, 1H), 4.42–
4.34 (m, 2H), 4.25 (q, J = 7.2 Hz, 2H), 1.41 (d, J = 6.6 Hz, 3H), 1.29 (t, J = 7.2 Hz, 3H). 
61b Ethyl 3,7-Dihydro-3-phenyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate 
White solid. Mp: 239 °C. Yield: 87%. MS: m/z 336.3 (M + H). 
1
H NMR (DMSO-d6): δ 
8.55 (s, 1H), 7.87–7.82 (m, 1H), 7.43–7.28 (m, 5H), 7.13–7.08 (m, 2H), 5.91 (m, 1H), 
4.76–4.64 (m, 2H), 4.19 (q, J = 6.2 Hz, 2H), 1.24 (t, J = 7 Hz, 3H). 
61c Ethyl 3,7-Dihydro-2-methyl-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 243–244 °C. Yield: 81%. MS: m/z 350.2 (M + H). 1H NMR (DMSO-
d6): δ 8.53 (s, 1H), 7.84–7.83 (m, 1H), 7.43–7.34 (m, 5H), 7.11–7.07 (m, 2H), 5.73 (d, J 
= 3 Hz, 1H), 4.82–4.78 (m, 1H), 4.21–4.16 (m, 2H), 1.27–1.18 (m, 6H). 
61d Ethyl 3,7-Dihydro-7-oxo-2,3-diphenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 289–290 °C dec. Yield: 75%. MS: m/z 412.1 (M + H). 1H NMR 
(DMSO-d6): δ 8.63 (s, 1H), 7.93–7.90 (m, 1H), 7.53–7.49 (m, 2H), 7.32–7.13 (m, 8H), 
6.66 (d, J = 6.4 Hz, 2H), 6.15–5.95 (m, 2H), 4.22–4.17 (m 2H), 1.25 (t, J = 7.2 Hz, 3H). 
61e Ethyl 3,7-Dihydro-9-methyl-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 199 °C dec. Yield: 79%. MS: m/z 350.0 (M + H). 
1
H NMR (DMSO-
d6): δ 8.49 (s, 1H), 7.63–7.62 (m, 1H), 7.36–7.32 (m, 3H), 7.13–7.04 (m, 3H), 5.87 (m, 
1H), 4.72–4.59 (m 2H), 4.16 (q, J = 6.4 Hz, 2H), 2.38 (s, 3H), 1.21 (t, J = 7 Hz, 3H). 
61f Ethyl 3,7-Dihydro-7-oxo-3-(4-methylphenyl)-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 183 °C. Yield: 83%. MS: m/z 350.2 (M + H). 
1
H NMR (DMSO-d6): δ 
8.50 (s, 1H), 7.86–7.81 (m, 1H), 7.43–7.27 (m, 2H), 7.18 (d, J = 7.8 Hz, 2H), 7.00 (d, J 
= 8 Hz, 2H), 5.84 (m, 1H), 4.72–4.61 (m, 2H), 4.18 (q, J = 7 Hz, 2H), 2.27 (s, 3H), 1.22 
(t, J = 7.2 Hz, 3H). 
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61g Ethyl 3-Cyclopropyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 190 °C. Yield: 77%. MS: m/z 300.3 (M + H). 
1
H NMR (DMSO-d6): δ 
8.70 (s, 1H), 7.82–7.76 (m, 1H), 7.37–7.32 (m, 2H), 4.58–4.31 (m, 2H), 4.24 (q, J = 7.2 
Hz, 2H), 3.97 (m, 1H), 1.29 (t, J = 7.2 Hz, 3H), 1.18 (m, 1H), 0.59 (m, 4H). 
61i Ethyl 3,7-Dihydro-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 133 °C. Yield: 80%. MS: m/z 302.2 (M + H). 
1
H NMR (DMSO-d6): δ 
8.60 (s, 1H); 7.79–7.74 (m, 1H), 7.36–7.30 (m, 2H), 4.60–4.54 (m, 2H), 4.28–4.21 (m, 
3H), 1.82–1.63 (m, 2H), 1.48–1.33 (m, 2H), 1.29 (d, J = 7.2 Hz, 3H), 0.89 (t, J = 7.2 
Hz, 3H). 
61j Ethyl 3,7-Dihydro-8-methyl-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
Pale white solid. Mp: 125–127 °C. Yield: 95%. MS: m/z 316.3 (M + H). 1H NMR 
(DMSO-d6): δ 8.47 (s, 1H), 7.16–7.07 (m, 2H), 4.79 (m, 1H), 4.53–4.47 (m, 2H), 4.24–
4.16 (m, 3H), 2.71 (s, 3H), 1.81–1.68 (m, 4H), 1.31–1.24 (m, 6H), 0.88 (t, J = 7.4 Hz, 
3H). 
 
Synthesis of ethyl 3-oxopropanoate derivatives (64a–c) 
 
Carbonyldiimidazole (11 mmol) was added to a solution of the requisite benzoic acid 
(63a–c, 10 mmol) in anhydrous THF (50 mL). After the mixture was stirred at room 
temperature for 6 h, the magnesium salt of ethyl malonic acid half-ester (prepared by 
stirring monoethyl malonate (10 mmol) and magnesium ethoxide (5 mmol) in 
anhydrous THF (25 mL) for 1 h at room temperature) was added, and the mixture was 
stirred at room temperature overnight. The solvent was removed under reduced 
pressure, and the residue was partitioned between 5% hydrochloric acid (20 mL) and 
ether (50 mL). The aqueous layer was further extracted with ether, and the combined 
extracts were washed with aqueous saturated sodium bicarbonate solution (10 mL) and 
dried. Evaporation of the solvent in vacuo led to the desired compounds as clear oils 
(79%), which were used without further purification in the next step. 
 
64a Ethyl 3-(2,3-Difluorophenyl)-3-oxopropanoate 
64b Ethyl 3-(2,3,4-Trifluorophenyl)-3-oxopropanoate 
64c Ethyl 3-(2,3,4,5-Tetrafluorophenyl)-3-oxopropanoate 
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Synthesis of 2-(ethoxymethylene)-3-oxo-3-phenyl-propionate derivatives (65a–i) 
 
A mixture of the appropriate ethyl 3-(2,3-difluorophenyl)-, 3-(2,3,4-trifluorophenyl)-, or 
3-(2,3,4,5-tetrafluorophenyl)-3-oxopropanoate (64a–c, 7.7 mmol), triethyl orthoformate 
(11.5 mmol), and acetic anhydride (45 mmol) was stirred at 110–120 °C for 3 h. The 
reaction was concentrated under reduced pressure to leave an oily residue, which was 
diluted with toluene and concentrated. This process was repeated two more times to 
afford the desired ethyl 2-(ethoxymethylene)-3-oxo-3-(2,3-difluorophenyl)-, 3-(2,3,4-
trifluorophenyl)-, or 3-(2,3,4,5-tetrafluorophenyl)propionate (65a–c) as an oil, which 
was used directly without further purification. 
 
Synthesis of Ethyl 2-benzoyl-3-((2-hydroxy-1-alkylethyl)amino)acrylates (66a–i) 
 
To a solution of ethyl 2-(ethoxymethylene)-3-oxo-3-(2,3-difluorophenyl)propionate 
(65a; 7.7 mmol) in dry methylene chloride (20 mL) was added a solution of the desired 
(R,S)-, (R)-, or (S)-2-amino-1-hydroxyalkane (11 mmol) in methylene chloride (5 mL) 
dropwise under cooling with an ice bath. The whole mixture was stirred at room 
temperature for 1 h and then concentrated in vacuo to yield the requisite (R,S)-, (R)-, or 
(S)-ethyl 2-(2,3-difluorobenzoyl)-3-((2-hydroxy-1-alkylethyl)amino)acrylates 66a–g as 
oils, which were used in the next step without further purification. 
In identical fashion, ethyl 2-(ethoxymethylene)-3-oxo-3-(2,3,4-trifluorophenyl) 
propionate (65b) or ethyl 2-(ethoxymethylene)-3-oxo-3-(2,3,4,5-tetrafluorophenyl) 
propionate (65c) was reacted with 2-amino-1-hydroxybutane to afford the desired ethyl 
2-(2,3,4-trifluorobenzoyl)-3-((2-hydroxy-1-ethylethyl)amino) acrylate (66h) and ethyl 
2-(2,3,4,5-tetrafluorobenzoyl)-3-((2-hydroxy-1-ethylethyl)amino) acrylate (66i) as oils, 
which were used in the next step without further purification. 
 
Synthesis of Ethyl 3,7-Dihydro-7-oxo-3-substituted-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxylates (67a–i) 
 
A mixture of the requisite ethyl 2-(2,3-difluorobenzoyl)-, 2-(2,3,4-trifluorobenzoyl)-, or 
2-(2,3,4,5-tetrafluorobenzoyl)-3-((2-hydroxy-1-substituted-ethyl)amino)acrylate (66a–i, 
5.5 mmol), K2CO3 (16 mmol), and anhydrous DMF (30 mL) was stirred at 130–140 °C 
for 7 h. After cooling, ethyl acetate (50 mL) was added to the reaction mixture. The 
organic phase was washed with water, dried, filtered, and concentrated. The residue was 
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purified by flash chromatography, eluting with ethyl acetate/petroleum ether (7/3) to 
afford the desired product as a white solid. 
 
(R)-67a (R)-Ethyl 3,7-Dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
(S)-67a (S)-Ethyl 3,7-Dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
The NMR data and melting points are identical to those reported for compound 61a. 
67b (R,S)-Ethyl 3,7-Dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate,  
(R)-67b (R)-Ethyl 3,7-Dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
(S)-67b (S)-Ethyl 3,7-Dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 157 °C dec. Yield: 86%. MS: m/z 288.3 (M + H). 
1
H NMR (DMSO-
d6): δ 8.63 (s, 1H), 7.79–7.44 (m, 1H), 7.35–7.30 (m, 2H), 4.61–4.49 (m, 2H), 4.32–
4.18 (m, 3H), 1.75–1.72 (m, 2H), 1.28 (t, J = 7 Hz, 3H), 0.93 (t, J = 7.6 Hz, 3H). 
67c (R,S)-Ethyl 3,7-Dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate,  
(R)-67c (R)-Ethyl 3,7-Dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
(S)-67c (S)-(-)-Ethyl 3,7-Dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxylate  
White solid. Mp: 142 °C. Yield: 71%. MS: m/z 302.2 (M + H). 
1
H NMR (DMSO-d6): δ 
8.60 (s, 1H), 7.79–7.74 (m, 1H), 7.39–7.29 (m, 2H), 4.75 (d, J = 10.8 Hz, 1H), 4.32–
4.18 (m, 4H), 2.07–1.91 (m, 1H), 1.28 (t, J = 7.2 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 0.81 
(d, J = 6.8 Hz, 3H). 
(R)-67d (R)-(+)-Ethyl 3,7-Dihydro-3-isobutyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxylate  
Colorless oil. Yield: 54%. MS: m/z 316.3 (M + H). 
1
H NMR (CDCl3): δ 8.33 (s, 1H), 
8.08–8.04 (m, 1H), 7.32–7.21 (m, 2H), 4.45–4.17 (m, 4H), 1.95–1.51 (m, 4H), 1.22 (m, 
3H), 1.05 (t, J = 6.4 Hz, 3H), 0.98 (d, J = 6 Hz, 3H). 
(R)-67e (R)-Ethyl 3,7-Dihydro-3-phenyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
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(S)-67e (S)-Ethyl 3,7-Dihydro-3-phenyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
The NMR data and melting points are identical to those reported for compound 11b. 
(R)-67f (R)-Ethyl 3,7-Dihydro-3-benzyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 179–180 °C. Yield: 57%. MS: m/z 350.4 (M + H). 1H NMR (DMSO-
d6): δ 8.74 (s, 1H), 8.07–8.03 (m, 1H), 7.74–7.39 (m, 2H), 7.23–7.16 (m, 5H), 5.33–
5.29 (m, 2H), 4.25 (q, J = 6.8 Hz, 2H), 3.83 (m, 2H), 3.26 (m, 1H), 1.30 (t, J = 7.2 Hz, 
3H). 
67g Ethyl 3,7-Dihydro-3,3-dimethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
Yellow solid. Mp: 216–217 °C. Yield: 28%. MS: m/z 289.3 (M + H). 1H NMR (CDCl3): 
δ 8.61 (s, 1H), 8.11–8.07 (m, 1H), 7.36–7.23 (m, 2H), 4.40 (q, J = 7.2 Hz, 2H), 4.12 (s, 
2H), 1.62 (s, 6H), 1.42 (t, J = 7.2 Hz, 3H). 
67h Ethyl 3,7-Dihydro-3-ethyl-10-fluoro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylate  
White solid. Mp: 190–191 °C dec. Yield: 40%. MS: m/z 306.1 (M + H). 1H NMR 
(DMSO-d6): δ 8.66 (s, 1H), 7.82–7.70 (m, 1H), 7.45–7.31 (m, 1H), 4.79–4.54 (m 2H), 
4.40–4.31 (m, 1H), 4.23 (q, J = 7 Hz, 2H), 1.91–1.83 (m, 2H), 1.28 (t, J = 7 Hz, 3H), 
0.94 (t, J = 7.4 Hz, 3H). 
67i Ethyl 3,7-Dihydro-3-ethyl-9,10-difluoro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-
6-carboxylate  
White solid. Mp: 190–191 °C dec. Yield: 40%. MS: m/z 324.2 (M + H). 1H NMR 
(DMSO-d6): δ 8.68 (s, 1H), 7.71–7.57 (m, 1H), 4.79–4.54 (m 2H), 4.40–4.33 (m, 1H), 
4.23 (q, J = 7 Hz, 2H), 1.82–1.63 (m, 2H), 1.28 (t, J = 7 Hz, 3H), 0.93 (t, J = 7.4 Hz, 
3H). 
 
Synthesis of 3,7-Dihydro-2/3-substituted-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-
6-carboxylic Acids (62a–g,i,j; 68a–i) 
 
A solution of the requisite ethyl 3,7-dihydro-2-substituted-3-substituted-7-oxo-2H-
[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate (61a–g,i,j, 67a–i, 7.4 mmol), NaOH 10% 
(10 mL), and methanol (90 mL) was heated at 80 °C for 1 h. The solvent was 
evaporated under reduced pressure, and the residue was acidified with 10% HCl at 0 °C. 
The precipitate was collected by filtration to give the desired product as a white solid. 
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62a (R,S)-3,7-Dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic 
Acid 
(R)-68a (R)-3,7-Dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid 
(S)-18a (S)-3,7-Dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 240 °C dec. Yield: 76%. MS: m/z 246.1 (M + H). 
1
H NMR (DMSO-
d6): δ 15.23 (br s, 1H), 9.05 (s, 1H), 7.95–7.91 (m, 1H), 7.60–7.47 (m, 2H), 4.99–4.84 
(m, 1H), 4.50–4.42 (m, 2H), 1.46 (d, J = 7 Hz, 3H). 
62b (R,S)-3,7-Dihydro-3-phenyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic 
Acid 
(R)-68e (R)-3-Phenyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
(S)-68e (S)-3-Phenyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 284 °C. Yield: 90%. MS: m/z 308.4 (M + H). 
1
H NMR (DMSO-d6): δ 
15.10 (br s, 1H), 8.90 (s, 1H), 8.02–7.98 (m, 1H),7.64–7.37 (m, 5H), 7.17–7.12 (m, 2H), 
6.10 (m, 1H), 4.85–4.83 (m, 1H), 4.73–4.70 (m, 1H). 
62c 3,7-Dihydro-2-methyl-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 291–292 °C dec. Yield: 82%. MS: m/z 322.4 (M + H). 1H NMR 
(DMSO-d6): δ 15.02 (br s, 1H), 8.93 (s, 1H), 8.02–7.98 (m, 1H), 7.61–7.56 (m, 2H), 
7.38–7.34 (m, 3H), 7.11–7.09 (m, 2H), 5.93–5.91 (m, 1H), 4.96–4.84 (m, 1H), 2.03 (m, 
3H). 
62d 3,7-Dihydro-7-oxo-2,3-diphenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic 
Acid  
White solid. Mp: >300 °C. Yield: 86%. MS: m/z 384.2 (M + H). 
1
H NMR (DMSO-d6): 
δ 15.03 (br s, 1H), 8.73 (s, 1H), 8.02–7.99 (m, 1H), 7.55–7.51 (m, 2H), 7.29–7.12 (m, 
8H), 6.71–6.67 (m, 2H), 6.20 (m, 1H), 5.95 (m, 1H). 
62e 3,7-Dihydro-9-methyl-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: >300 °C. Yield: 86%. MS: m/z 322.5 (M + H). 
1
H NMR (DMSO-d6): 
δ 15.21 (br s, 1H), 8.85 (s, 1H), 7.81–7.79 (m, 1H), 7.39–7.35 (m, 4H), 7.15–7.10 (m, 
2H), 6.08 (m, 1H), 4.83–4.69 (m, 2H), 2.48 (s, 3H). 
7. Experimental Section 
77 
62f 3,7-Dihydro-7-oxo-3-(4-methylphenyl)-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 294 °C dec. Yield: 90%. MS: m/z 322.2 (M + H). 
1
H NMR (DMSO-
d6): δ 15.08 (br s, 1H), 8.82 (s, 1H), 8.01–7.96 (m, 1H), 7.63–7.47 (m, 2H), 7.20 (d, J = 
8 Hz, 2H), 7.06 (d, J = 8.4 Hz, 2H), 6.02 (m, 1H), 4.80–4.69 (m, 2H), 2.28 (s, 3H). 
62g 3-Cyclopropyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic 
Acid  
White solid. Mp: 227–228 °C. Yield: 76%. MS: m/z 272.1 (M + H). 1H NMR (DMSO-
d6): δ 15.17 (br s, 1H), 9.06 (s, 1H), 7.95–7.90 (m, 1H), 7.59–7.46 (m, 2H), 4.64–4.46 
(m, 2H), 4.14–4.07 (m, 1H), 1.38–1.11 (m, 1H), 0.79–0.52 (m, 4H). 
62i 3,7-Dihydro-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid  
White solid. Mp: 213 °C. Yield: 82%. MS: m/z 274.3 (M + H). 
1
H NMR (DMSO-d6): δ 
15.21 (br s, 1H), 9.00 (s, 1H), 7.95–7.90 (m, 1H), 7.60–7.46 (m, 2H), 4.85 (m, 1H), 
4.69–4.63 (m, 1H), 4.42–4.41 (m, 1H), 1.98–1.11 (m, 4H), 0.88 (t, J = 7 Hz, 3H). 
62j 3,7-Dihydro-8-methyl-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 205 °C dec. Yield: 78%. MS: m/z 289.2 (M + H). 
1
H NMR (DMSO-
d6): δ 15.53 (br s, 1H), 8.91 (s, 1H), 7.36–7.24 (m, 2H), 4.84–4.77 (m, 1H), 4.59 (d, J = 
11.4 Hz, 1H), 4.29 (d, J = 10 Hz, 1H), 2.80 (s, 3H), 1.95–1.20 (m, 4H), 0.87 (t, J = 7.4 
Hz, 3H). 
68b (R,S)-3,7-Dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic 
Acid  
(R)-68b (R)-3,7-Dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid 
(S)-18b (S)-3,7-Dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic 
Acid  
White solid. Mp: 190 °C. Yield: 78%. MS: m/z 260.1 (M + H). 
1
H NMR (DMSO-d6): δ 
15.21 (br s, 1H), 9.03 (s, 1H), 7.94–7.90 (m, 1H), 7.59–7.45 (m, 2H), 4.81–4.65 (m, 
2H), 4.42–4.35 (m, 1H), 1.80–1.75 (m, 2H), 0.93 (t, J = 6.6 Hz, 3H). 
68c (R,S)-3,7-Dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid 
(R)-68c (R)-3,7-Dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid 
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(S)-68c (S)-3,7-Dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 210 °C. Yield: 86%. MS: m/z 274.2 (M + H). 
1
H NMR (DMSO-d6): δ 
14.99 (br s, 1H), 8.99 (s, 1H), 8.31–7.44 (m, 3H), 5.28 (m, 1H), 4.99–3.91 (m, 3H), 2.01 
(m, 1H), 1.28 (t, J = 7.2 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H). 
(R)-68d (R)-3,7-Dihydro-3-isobutyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 131–132 °C. Yield: 80%. MS: m/z 288.3 (M + H). 1H NMR (DMSO-
d6): δ 14.99 (br s, 1H), 8.62 (s, 1H), 8.11–8.06 (m, 1H), 7.52–7.26 (m, 2H), 4.82–4.21 
(m, 3H), 1.99–1.38 (m, 3H), 1.07–0.95 (m, 6H). 
(R)-68f (R)-3-Benzyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 239–240 °C. Yield: 82%. MS: m/z 323.2 (M + H). 1H NMR (DMSO-
d6): δ 15.08 (br s, 1H), 8.58 (s, 1H), 7.97–7.92 (m, 1H), 7.63–7.54 (m, 2H), 7.31–7.14 
(m, 5H), 5.08 (m, 1H), 4.59–4.15 (m, 2H), 3.13–3.05 (m, 2H). 
68g 3,7-Dihydro-3,3-dimethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic 
Acid  
White solid. Mp: >300 °C. Yield: 68%. MS: m/z 260.1 (M + H). 
1
H NMR (CDCl3): δ 
15.00 (br s, 1H), 8.88 (s, 1H), 8.15–8.10 (m, 1H), 7.53–7.36 (m, 2H), 4.18 (s, 2H), 1.67 
(s, 6H). 
68h 3-Ethyl-10-fluoro-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 230 °C. Yield: 65%. MS: m/z 278.1 (M + H). 
1
H NMR (DMSO-d6): δ 
15.00 (br s, 1H), 9.01 (s, 1H), 7.97–7.90 (m, 1H), 7.64–7.54 (m, 1H), 4.84–4.75 (m, 
2H), 4.64–4.39 (m, 1H), 1.85–1.73 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 
68i 9,10-Difluoro-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic Acid  
White solid. Mp: 246–248 °C. Yield: 50%. MS: m/z 296.3 (M + H). 1H NMR (DMSO-
d6): δ 15.00 (br s, 1H), 9.01 (s, 1H), 7.71–7.65 (m, 1H), 4.84–4.76 (m, 2H), 4.44–4.38 
(m, 1H), 1.84–1.76 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H). 
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Synthesis of N-Cycloalkyl- or N,N-Diisopropyl-3,7-dihydro-2/3-substituted-7-oxo-
2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides 
 
To a solution of the appropriate 3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-
6-carboxylic acid (62, (R)-68a, (S)-68a, 68b, 0.6 mmol) in DMF (5 mL) were added 
EDC (0.6 mmol), HOBt (0.6 mmol), and finally the desired amine (0.9 mmol). The 
reaction mixture was stirred at room temperature for 6 h. The solvent was evaporated, 
and the residue was purified by column chromatography to yield a white solid. 
 
69 N-Cyclopentyl-3,7-dihydro-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 237 °C. Yield: 64%. MS: m/z 375.2 (M + H). 
1
H NMR (DMSO-d6): 
10.00 (br d, J = 7.2 Hz, 1H), 8.67 (s, 1H), 7.96–7.91 (m, 1H), 7.46–7.36 (m, 5H), 7.14–
7.09 (m, 2H), 6.01 (m, 1H), 4.82–4.59 (m, 2H), 4.25–4.16 (m, 1H), 1.98–1.30 (m, 8H). 
Anal. (C23H22N2O3) C, H, N. 
70 N-Cyclohexyl-3,7-dihydro-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 207 °C. Yield: 58%. MS: m/z 389.5 (M + H). 
1
H NMR (DMSO-d6): δ 
10.01 (br d, J = 7.6 Hz, 1H), 8.69(s, 1H), 7.96–7.91 (m, 1H), 7.49–7.08 (m, 7H), 6.01 
(m, 1H), 4.76 (m, 1H), 4.65 (m, 1H), 3.95 (m, 1H), 1.88–1.30 (m, 10H). Anal. 
(C24H24N2O3) C, H, N. 
71 N-Cycloheptyl-3,7-dihydro-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 169 °C. Yield: 55%. MS: m/z 403.5 (M + H). 
1
H NMR (DMSO-d6): δ 
10.03 (br d, J = 7.8 Hz, 1H), 8.66 (s, 1H), 7.96–7.92 (m, 1H), 7.46–7.34 (m, 5H), 7.14–
7.09 (m, 2H), 6.01 (m, 1H), 4.83–4.58 (m, 2H), 3.95 (m, 1H), 1.95–1.35 (m, 12H). 
Anal. (C25H26N2O3) C, H, N. 
74 N-Cyclohexyl-3,7-dihydro-2-methyl-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 254 °C. Yield: 61%. MS: m/z 403.3 (M + H). 
1
H NMR (DMSO-d6): δ 
9.97 (br d, J = 7.4 Hz, 1H), 8.68 (s, 1H), 7.97–7.93 (m, 1H), 7.50–7.35 (m, 5H), 7.10 
(m, 2H), 5.88 (m, 1H), 4.89–4.84 (m, 1H), 3.91 (m, 1H), 1.97–1.40 (m, 10H), 1.33 (d, J 
= 6.2 Hz, 3H). Anal. (C25H26N2O3) C, H, N. 
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77 N-Cyclohexyl-3,7-dihydro-7-oxo-3-p-tolyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 237 °C. Yield: 64%. MS: m/z 403.4 (M + H). 
1
H NMR (DMSO-d6): δ 
9.99 (br d, J = 7.4 Hz, 1H), 8.62 (s, 1H), 7.95–7.90 (m, 1H), 7.49–7.34 (m, 2H), 7.19 (d, 
J = 8.00 Hz, 2H), 7.02 (d, J = 8.00 Hz, 2H), 5.94 (m, 1H), 4.72–4.63 (m, 2H), 3.89 (m, 
1H), 2.28 (s, 3H), 1.92–1.26 (m, 10H). Anal. (C25H26N2O3) C, H, N. 
79 N-Cyclohexyl-3,7-dihydro-9-methyl-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-
ij]quinoline-6-carboxamide  
White solid. Mp: 286 °C. Yield: 66%. MS: m/z 403.5 (M + H). 
1
H NMR (DMSO-d6): δ 
10.04 (br d, J = 7.8 Hz, 1H), 8.63 (s, 1H), 7.74 (s, 1H), 7.38–7.35 (m, 3H), 7.21 (s, 1H), 
7.011–7.07 (m, 2H), 5.99 (m, 1H), 4.75–4.59 (m, 2H), 3.89 (m, 1H), 2.43 (s, 3H), 1.92–
1.24 (m, 10H). Anal. (C25H26N2O3) C, H, N. 
81 N-Cyclohexyl-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 245 °C. Yield: 58%. MS: m/z 327.2 (M + H). 
1
H NMR (DMSO-d6): δ 
10.05 (br d, J = 7.8 Hz, 1H), 8.82 (s, 1H), 7.89–7.85 (m, 1H), 7.46–7.33 (m, 2H), 4.82 
(m, 1H), 4.45–4.36 (m, 2H), 3.81 (m, 1H), 1.88–1.28 (m, 13H). Anal. (C19H22N2O3) C, 
H, N. 
82 N-Cycloheptyl-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 208 °C. Yield: 47%. MS: m/z 403.3 (M + H). 
1
H NMR (CDCl3): δ 
10.05 (br d, J = 7.4 Hz, 1H), 8.71 (s, 1H), 8.09–8.04 (m, 1H), 7.41–7.24 (m, 2H), 4.82 
(m, 1H), 4.35–4.26 (m, 2H), 4.21–4.08 (m, 1H), 2.04–1.97 (m, 2H), 1.71–1.57 (m, 
13H). Anal. (C20H24N2O3) C, H, N. 
84 N-Cyclohexyl-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 175 °C. Yield: 69%. MS: m/z 341.3 (M + H). 
1
H NMR (DMSO-d6): δ 
10.05 (br d, J = 7.8 Hz, 1H), 8.80 (s, 1H), 7.89–7.84 (m, 1H), 7.46–7.32 (m, 2H), 4.67–
4.60 (m, 2H), 4.36–4.30 (m, 1H), 3.99 (m, 1H), 1.87–1.28 (m, 12H), 0.92 (t, J = 7.4 Hz, 
3H). Anal. (C20H24N2O3) C, H, N. 
85 N-Cycloheptyl-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 165 °C. Yield: 51%. MS: m/z 355.3 (M + H). 
1
H NMR (DMSO-d6): δ 
10.09 (br d, J = 7.8 Hz, 1H), 8.79 (s, 1H), 7.89–7.84 (m, 1H), 7.41–7.35 (m, 2H), 4.70–
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4.59 (m, 2H), 4.36–4.29 (m, 1H), 4.07–4.01 (m, 1H), 1.87–1.56 (m, 14H), 0.92 (t, J = 
7.2 Hz, 3H). Anal. (C21H26N2O3) C, H, N. 
91 3,7-Dihydro-N,N-diisopropyl-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 187 °C. Yield: 36%. MS: m/z 336.2 (M + H). 
1
H NMR (DMSO-
d6):8.06 (s, 1H), 7.74–7.69 (m, 1H), 7.27–7.23 (m, 2H), 4.63–4.21 (m, 3H), 3.75 (m, 
1H), 3.50 (m, 1H), 1.80–1.42 (m, 2H), 1.42 (d, J = 6.4 Hz, 6H), 1.08 (m, 6H), 0.90 (t, J 
= 7.2 Hz, 3H). Anal. (C20H26N3O3) C, H, N. 
92 N-Cyclohexyl-3,7-dihydro-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 191 °C. Yield: 68%. MS: m/z 355.2 (M + H). 
1
H NMR (DMSO-d6): δ 
10.04 (br d, J = 8 Hz, 1H), 8.77 (s, 1H), 7.87–7.85 (m, 1H), 7.43–7.33 (m, 2H), 4.75–
4.59 (m, 2H), 4.34–4.31 (m, 1H), 3.85 (m, 1H), 1.91–1.29 (m, 14H), 0.87 (t, J = 7.6 Hz, 
3H). Anal. (C21H26N2O3) C, H, N. 
93 N-Cycloheptyl-3,7-dihydro-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: >300 °C. Yield: 46%. MS: m/z 369.6 (M + H). 
1
H NMR (DMSO-d6): 
δ 10.08 (br d, J = 8 Hz, 1H), 8.75 (s, 1H), 7.89–7.84 (m, 1H), 7.45–7.31 (m, 2H), 4.74–
4.57 (m, 2H), 4.34–4.29 (m, 1H), 4.04 (m, 1H), 3.98 (m, 1H), 1.89–1.29 (m, 15H), 0.88 
(t, J = 7.2 Hz, 3H). Anal. (C22H28N2O3) C, H, N. 
96 N-Cyclohexyl-3,7-dihydro-8-methyl-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 213 °C. Yield: 55%. MS: m/z 369.4 (M + H). 
1
H NMR (DMSO-d6): δ 
10.05 (br d, J = 7.8 Hz, 1H); 8.67 (s, 1H), 7.22–7.08 (m, 2H); 4.73–4.65 (m, 1H); 4.56–
4.50 (m, 1H); 4.26–4.19 (m, 1H); 3.82 (m, 1H); 2.78 (s, 3H); 1.88–1.19 (m, 14H); 0.87 
(t, J = 7.4 Hz, 3H). Anal. (C22H28N2O3) C, H, N. 
98 N-Cyclohexyl-3-cyclopropyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-
6-carboxamide  
White solid. Mp: 212 °C. Yield: 63%. MS: m/z 353.2 (M + H). 
1
H NMR (DMSO-d6): δ 
10.05 (br d, J = 8 Hz, 1H), 8.90 (s, 1H), 7.90–7.86 (m, 1H), 7.43–7.38 (m, 2H), 4.61–
4.46 (m, 2H), 4.10–4.05 (m, 1H), 3.85 (m, 1H), 1.99–1.32 (m, 11H), 0.70.65 (m, 4H). 
Anal. (C21H24N2O3) C, H, N. 
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99 N-Cycloheptyl-3-cyclopropyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-
6-carboxamide  
White solid. Mp: 185 °C. Yield: 52%. MS: m/z 367.6 (M + H). 
1
H NMR (DMSO-d6): δ 
10.09 (br d, J = 8.4 Hz, 1H), 8.90 (s, 1H), 7.89–7.87 (m, 1H), 7.45–7.35 (m, 2H), 4.55–
4.46 (m, 2H), 4.05–4.02 (m, 2H), 1.99–1.90 (m, 2H),1.69–1.41 (m, 10H), 1.30–1.19 (m, 
1H), 0.75–0.54 (m, 4H). Anal. (C22H26N2O3) C, H, N. 
(R)-91 (R)-N-Cyclohexyl-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 245 °C. Yield: 62%. MS: m/z 327.2 (M + H). 
1
H NMR (DMSO-d6): δ 
10.05 (br d, J = 7.8 Hz, 1H), 8.82 (s, 1H), 7.89–7.85 (m, 1H), 7.46–7.33 (m, 2H), 4.82 
(m, 1H), 4.45–4.36 (m, 2H), 3.81 (m, 1H), 1.88–1.28 (m, 13H). Anal. (C19H22N2O3) C, 
H, N. [α]D
25
 = +81 (c = 0.01, CH3OH). 
(S)-91 (S)-N-Cyclohexyl-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 245 °C. Yield: 69%. MS: m/z 327.2 (M + H). 
1
H NMR (DMSO-d6): δ 
10.05 (br d, J = 7.8 Hz, 1H), 8.82 (s, 1H), 7.89–7.85 (m, 1H), 7.42–7.37 (m, 2H), 4.82 
(m, 1H), 4.49–4.37 (m, 2H), 3.81 (m, 1H), 1.88–1.28 (m, 13H). Anal. (C19H22N2O3) C, 
H, N. [α]D
25
 = −81 (c = 0.01, CH3OH). 
(R)-95 (R)-(+)-N-Cycloheptyl-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 165 °C. Yield: 72%. MS: m/z 355.3 (M + H). 
1
H NMR (DMSO-d6): δ 
10.09 (br d, J = 7.8 Hz, 1H), 8.79 (s, 1H), 7.89–7.84 (m, 1H), 7.45–7.35 (m, 2H), 4.71–
4.60 (m, 2H), 4.36–4.29 (m, 1H), 4.07–4.01 (m, 1H), 1.87–1.56 (m, 14H), 0.92 (t, J = 
7.2 Hz, 3H). Anal. (C21H26N2O3) C, H, N. [α]D
25
 = +100 (c = 0.01, CHCl3). 
(S)-95 (S)-(-)-N-Cycloheptyl-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 165 °C. Yield: 54%. MS: m/z 355.0 (M + H). 
1
H NMR (DMSO-d6): δ 
10.09 (br d, J = 7.8 Hz, 1H), 8.79 (s, 1H), 7.89–7.84 (m, 1H), 7.45–7.32 (m, 2H), 4.70–
4.60 (m, 2H), 4.36–4.29 (m, 1H), 4.07–4.03 (m, 1H), 1.87–1.57 (m, 14H), 0.92 (t, J = 
7.2 Hz, 3H). Anal. (C21H26N2O3) C, H, N. [α]D
25
 = −100 (c = 0.01, CHCl3). 
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Synthesis of N-Adamantyl-, N-Alkyl-, and N-Heteroaryl-3,7-dihydro-2/3-
substituted-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides 
 
To a stirred solution of the respective carboxylic acid (62a–g,i,j, 68a–i, 0.2 mmol) in 
dry DMF (3 mL) was added diisopropylethylamine (0.8 mmol). The resulting solution 
was stirred at room temperature for 10 min before addition of HBTU (0.3 mmol) and 
then stirred for another 3 h. 1-Aminoadamantane, 2-aminoadamantane (for 87), or 1-
amino-3,5-dimethyladamantane (for 95) (0.3 mmol) was then added, and the solution 
was stirred for 16 h. DMF was evaporated under reduced pressure, and the residue was 
dissolved in ethyl acetate and successively washed with water-saturated sodium 
bicarbonate, water, and brine. The organic phase was dried over anhydrous sodium 
sulfate, evaporated, and finally purified by flash chromatography using ethyl 
acetate/petroleum ether (8/2) as the eluent. 
 
72 N-Adamant-1-yl-3,7-dihydro-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: >300 °C. Yield: 71%. MS: m/z 441.6 (M + H). 
1
H NMR (DMSO-d6): 
δ 9.89 (br s, 1H), 8.59 (s, 1H), 7.95–7.90 (m, 1H), 7.45–7.34 (m, 5H), 7.16–7.11 (m, 
2H), 5.96 (m, 1H); 4.92–4.58 (m, 2H), 2.03 (s, 9H), 1.65 (s, 6H). Anal. (C28H28N2O3) C, 
H, N. 
73 3,7-Dihydro-N-(3,5-dimethyladamant-1-yl)-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-
ij]quinoline-6-carboxamide  
White solid. Mp: 264 °C. Yield: 63%. MS: m/z 469.5 (M + H). 
1
H NMR (DMSO-d6): 
9.92 (br s, 1H), 8.56 (s, 1H), 7.95–7.90 (m, 1H), 7.45–7.37 (m, 5H), 7.17–7.12 (m, 2H), 
5.95 (m, 1H), 4.82–4.59 (m, 2H), 2.10–1.59 (m, 7H), 1.39–1.14 (m, 6H), 0.83 (s, 6H). 
Anal. (C30H32N2O3) C, H, N. 
75 N-Adamant-1-yl-3,7-dihydro-2-methyl-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: >300 °C. Yield: 71%. MS: m/z 455.6 (M + H). 
1
H NMR (DMSO-d6): 
9.85 (br s, 1H), 8.62 (s, 1H), 7.95–7.91 (m, 1H), 7.52–7.33 (m, 5H), 7.11–7.06 (m, 2H), 
5.82 (d, J = 2.8 Hz, 1H), 4.83–4.78 (m, 1H), 2.02 (s, 9H), 1.64 (s, 6H), 1.20 (d, J = 6.2 
Hz, 3H). Anal. (C29H30N2O3) C, H, N. 
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76 N-Adamant-1-yl-3,7-dihydro-7-oxo-2,3-diphenyl-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide 
White solid. Mp: 260 °C. Yield: 45%. MS: m/z 517.3 (M + H). 
1
H NMR (DMSO-d6): 
9.86 (br s, 1H), 8.73 (s, 1H), 8.02–7.98 (m, 1H), 7.58–7.54 (m, 2H), 7.33–7.13(m, 8H), 
6.71–6.66 (m, 2H), 6.25 (d, J = 2.8 Hz, 1H), 5.96 (d, J = 2.8 Hz, 1H), 2.04 (s, 9H), 1.65 
(s, 6H). Anal. (C34H32N2O3) C, H, N. 
78 N-Adamant-1-yl-3,7-dihydro-7-oxo-3-(4-methylphenyl)-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 171 °C. Yield: 59%. MS: m/z 455.8 (M + H). 
1
H NMR (DMSO-d6): δ 
9.89 (br s, 1H), 8.53 (s, 1H), 7.94–7.89 (m, 1H), 7.45–7.34 (m, 2H), 7.21 (d, J = 8.00 
Hz, 2H), 7.06 (d, J = 8.00 Hz, 2H), 5.88 (m, 1H), 4.79–4.51 (m, 2H), 2.29 (s, 3H), 2.03 
(s, 9H), 1.65 (s, 6H). Anal. (C29H30N2O3) C, H, N. 
80 N-Adamant-1-yl-3,7-dihydro-9-methyl-7-oxo-3-phenyl-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: >300 °C. Yield: 48%. MS: m/z 455.4 (M + H). 
1
H NMR (DMSO-d6): 
δ 9.93 (br s, 1H), 8.55 (s, 1H), 7.73 (s, 1H), 7.39–7.36 (m, 3H), 7.20 (s, 1H), 7.14–7.10 
(m, 2H), 5.94 (m, 1H), 4.82–4.53 (m, 2H), 2.43 (s, 3H), 2.03 (s, 9H), 1.65 (s, 6H). Anal. 
(C29H30N2O3) C, H, N. 
83 N-Adamant-1-yl-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 282 °C. Yield: 55%. MS: m/z 379.3 (M + H). 
1
H NMR (DMSO-d6): δ 
9.95 (br s, 1H), 8.77 (s, 1H), 7.88–7.84 (m, 1H), 7.45–7.33 (m, 2H), 4.82 (m, 1H), 4.52–
4.23 (m, 2H), 2.07 (s, 9H), 1.67 (s, 6H), 1.42 (d, J = 6.8 Hz, 3H). Anal. (C23H26N2O3) C, 
H, N. 
86 N-Adamant-1-yl-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 219 °C. Yield: 66%. MS: m/z 393.5 (M + H). 
1
H NMR (DMSO-d6): δ 
9.93 (br s, 1H), 8.74 (s, 1H), 7.88–7.83 (m, 1H), 7.41–7.34 (m, 2H), 4.65–4.59 (m, 2H), 
4.39–4.12 (m, 1H), 2.07 (s, 9H), 1.72 (m, 2H), 1.67 (s, 6H), 0.92 (t, J = 7.4 Hz, 3H). 
Anal. (C24H28N2O3) C, H, N. 
87 N-Adamant-2-yl-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 240 °C. Yield: 45%. MS: m/z 393.1 (M + H). 
1
H NMR (DMSO-d6): 
10.61 (d, J = 8.4 Hz, 1H), 8.81 (s, 1H), 7.92–7.87 (m, 1H), 7.46–7.32 (m, 2H), 4.70–
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4.60 (m, 2H), 4.36–4.30 (m, 1H), 4.13 (d, J = 8.4 Hz, 1H), 1.98–1.60 (m, 16H), 0.96 (t, 
J = 7.2 Hz 3H). Anal. (C24H28N2O3) C, H, N. 
88 3,7-Dihydro-3-ethyl-N-(5-methylhexan-2-yl)-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 240 °C. Yield: 24%. MS: m/z 357.1 (M + H). 
1
H NMR (DMSO-d6): 
10.61 (d, J = 8.4 Hz, 1H), 8.80 (s, 1H), 7.88–7.80 (m, 1H), 7.48–7.34 (m, 2H), 4.78–
4.66 (m, 2H), 4.40–4.28 (m, 1H), 4.12–3.88 (m, 1H), 1.83–1.40 (m, 5H), 1.18–1.11 (m, 
5H), 0.88–0.83 (m, 9H). Anal. (C21H28N2O3) C, H, N. 
89 3,7-Dihydro-3-ethyl-7-oxo-N-pyridin-4-yl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 280 °C. Yield: 44%. MS: m/z 336.2 (M + H). 
1
H NMR (DMSO-d6): 
12.68 (br s, 1H), 9.00 (s, 1H), 8.50–8.47 (m, 2H), 7.97–7.93 (m, 1H), 7.74–7.70 (m, 
2H), 7.54–7.39 (m, 2H), 4.83–4.64 (m, 2H), 4.42–4.31 (m, 1H), 1.96–1.65 (m, 2H), 
0.95 (t, J = 7.6 Hz, 3H). Anal. (C19H17N3O3) C, H, N. 
90 3,7-Dihydro-3-ethyl-7-oxo-N-thiazol-2-yl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 221 °C. Yield: 58%. MS: m/z 342.2 (M + H). 
1
H NMR (DMSO-d6): 
13.62 (s, 1H), 9.05 (s, 1H), 7.96–7.94 (m, 1H), 7.54–7.28 (m, 4H), 4.78–4.65 (m, 2H), 
4.43–4.3 (m, 1H), 1.92–1.61 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). Anal. (C17H15N3O3S) C, 
H, N. 
94 N-Adamant-1-yl-3,7-dihydro-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxamide  
White solid. Mp: 218 °C. Yield: 43%. MS: m/z 407.3 (M + H). 
1
H NMR (DMSO-d6): δ 
9.93 (br s, 1H), 8.71 (s, 1H), 7.86–7.84 (m, 1H), 7.42–7.32 (m, 2H), 4.71 (m, 1H), 4.61–
4.58 (m, 1H), 4.33–4.30 (m, 1H), 2.06 (s, 9H), 1.78 (m, 2H), 1.67 (s, 6H), 1.43–1.21 (m, 
2H), 0.89 (t, J = 7.2 Hz, 3H). Anal. (C25H30N2O3) C, H, N. 
95 3,7-Dihydro-N-(3,5-dimethyladamant-1-yl)-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-
ij]quinoline-6-carboxamide  
White solid. Mp: 219 °C. Yield: 48%. MS: m/z 435.7 (M + H). 
1
H NMR (DMSO-d6): 
9.96 (br s, 1H), 8.68 (s, 1H), 7.87–7.83 (m, 1H), 7.45–7.31 (m, 2H), 4.79–4.57 (m, 2H), 
4.33 (m, 1H), 2.12–1.15 (m, 17H), 0.92–0.85 (m, 9H). Anal. (C27H34N2O3) C, H, N. 
97 N-Adamant-1-yl-3,7-dihydro-8-methyl-7-oxo-3-propyl-2H-[1,4]oxazino[2,3,4-
ij]quinoline-6-carboxamide  
White solid. Mp: 237 °C. Yield: 53%. MS: m/z 421.3 (M + H). 
1
H NMR (DMSO-d6): 
9.94 (br s, 1H), 8.62 (s, 1H), 7.17–7.05 (m, 2H), 4.85–4.60 (m, 2H), 4.22 (m, 1H), 3.43–
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3.36 (m, 4H), 2.77 (s, 3H), 2.06 (s, 9H), 1.67 (s, 6H), 0.88 (m, 3H). Anal. (C26H32N2O3) 
C, H, N. 
100 N-Adamant-1-yl-3-cyclopropyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 245 °C. Yield: 55%. MS: m/z 405.3 (M + H). 
1
H NMR (DMSO-d6): δ 
9.94 (br s, 1H), 8.88 (s, 1H), 7.89–7.85 (m, 1H), 7.42–7.36 (m, 2H), 4.63–4.18 (m, 2H), 
4.04–3.97 (m, 2H), 2.07 (s, 9H), 1.68 (s, 6H), 1.33–1.15 (m, 1H), 0.66–0.51 (m, 4H). 
Anal. (C25H28N2O3) C, H, N. 
101 N-Adamant-1-yl-3,7-dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 220 °C. Yield: 62%. MS: m/z 407.5 (M + H). 
1
H NMR (DMSO-d6): δ 
9.90 (br s, 1H), 8.68 (s, 1H), 7.85–7.81 (m, 1H), 7.42–7.28 (m, 2H), 4.79–4.73 (m, 1H), 
4.42–4.24 (m, 2H), 2.04 (s, 10H), 1.92 (m, 1H), 1.65 (s, 6H), 0.99 (d, J = 6.6 Hz, 3H), 
0.75 (d, J = 6.6 Hz, 3H). Anal. (C25H30N2O3) C, H, N. 
102 N-Adamant-1-yl-3,7-dihydro-3,3-dimethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
Pale white solid. Mp: 223 °C. Yield: 26%. MS: m/z 393.1 (M + H). 
1
H NMR (CDCl3): 
9.98 (br s, 1H), 8.95 (s, 1H), 8.10–8.05 (m, 1H), 7.41–7.23 (m, 2H), 4.12 (s, 2H), 2.19–
2.11 (m, 9H), 1.73 (s, 6H), 1.62 (s, 6H). Anal. (C24H28N2O3) C, H, N. 
103 N-Adamant-1-yl-3-ethyl-10-fluoro-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 232 °C. Yield: 65%. MS: m/z 411.2 (M + H). 
1
H NMR (DMSO-d6): δ 
9.84 (s, 1H), 8.77 (s, 1H), 7.90–7.82 (m, 1H), 7.48–7.38 (m, 1H), 4.75–4.64 (m, 2H), 
4.39–4.32 (m, 1H), 2.06 (s, 9H), 1.82–1.74 (m, 2H), 1.67 (s, 6H), 0.93 (t, J = 7.6 Hz, 
3H). Anal. (C24H27FN2O3) C, H, N. 
104 N-Adamant-1-yl-9,10-difluoro-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 262 °C. Yield: 50%. MS: m/z 429.3 (M + H). 
1
H NMR (DMSO-d6): δ 
9.78 (s, 1H), 8.79 (s, 1H), 7.77–7.68 (m, 1H), 4.82–4.68 (m, 2H), 4.45–4.38 (m, 1H), 
2.06 (s, 9H), 1.82–1.78 (m, 2H), 1.67 (s, 6H), 0.92 (t, J = 7.6 Hz, 3H). Anal. 
(C24H26FN2O3) C, H, N. 
(R)-83 (R)-(+)-N-Adamant-1-yl-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 282 °C. Yield: 56%. MS: m/z 379.3 (M + H). 
1
H NMR (DMSO-d6): δ 
9.95 (br s, 1H), 8.77 (s, 1H), 7.88–7.84 (m, 1H), 7.45–7.33 (m, 2H), 4.82 (m, 1H), 4.52–
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4.23 (m, 2H), 2.07 (s, 9H), 1.67 (s, 6H), 1.42 (d, J = 6.8 Hz, 3H). Anal. (C23H26N2O3) C, 
H, N. [α]D
25
 = +69 (c = 0.01, CDCl3). 
(S)-83 (S)-(-)-N-Adamant-1-yl-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 282 °C. Yield: 50%. MS: m/z 379.3 (M + H). 
1
H NMR (DMSO-d6): δ 
9.95 (br s, 1H), 8.77 (s, 1H), 7.88–7.84 (m, 1H), 7.45–7.33 (m, 2H), 4.82 (m, 1H), 4.52–
4.23 (m, 2H), 2.07 (s, 9H), 1.67 (s, 6H), 1.42 (d, J = 6.8 Hz, 3H). Anal. (C23H26N2O3) C, 
H, N. [α]D
25
 = −69 (c = 0.01, CDCl3). 
(R)-86 (R)-(+)-N-Adamant-1-yl-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 219 °C. Yield: 69%. MS: m/z 393.1 (M + H). 
1
H NMR (DMSO-d6): δ 
9.94 (br s, 1H), 8.75 (s, 1H), 7.88–7.83 (m, 1H), 7.41–7.34 (m, 2H), 4.65–4.59 (m, 2H), 
4.39–4.12 (m, 1H), 2.07 (s, 9H), 1.72 (m, 2H), 1.67 (s, 6H), 0.92 (t, J = 7.4 Hz, 3H). 
Anal. (C24H28N2O3) C, H, N. [α]D
25
 = +142 (c = 0.01, CHCl3). 
(S)-86 (S)-(-)-N-Adamant-1-yl-3,7-dihydro-3-ethyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 219 °C. Yield: 53%. MS: m/z 393.2 (M + H). 
1
H NMR (DMSO-d6): δ 
9.94 (br s, 1H), 8.75 (s, 1H), 7.88–7.83 (m, 1H), 7.45–7.31 (m, 2H), 4.65–4.59 (m, 2H), 
4.39–4.12 (m, 1H), 2.07 (s, 9H), 1.77 (m, 2H), 1.68 (s, 6H), 0.92 (t, J = 7.4 Hz, 3H). 
Anal. (C24H28N2O3) C, H, N. [α]D
25
 = −142 (c = 0.01, CHCl3). 
(R)-101 (R)-(+)-N-Adamant-1-yl-3,7-dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino 
[2,3,4-ij]quinoline-6-carboxamide  
White solid. Mp: 212 °C. Yield: 47%. MS: m/z 407.5 (M + H). 
1
H NMR (DMSO-d6): δ 
9.90 (br s, 1H), 8.68 (s, 1H), 7.86–7.81 (m, 1H), 7.42–7.28 (m, 2H), 4.79–4.73 (m, 1H), 
4.42–4.24 (m, 2H), 2.04 (s, 10H), 1.92 (m, 1H), 1.65 (s, 6H), 0.98 (d, J = 6.6 Hz, 3H), 
0.76 (d, J = 6.6 Hz, 3H). Anal. (C25H30N2O3) C, H, N. [α]D
25
 = +42 (c = 0.01, CH3OH). 
(S)-101 (S)-(-)-N-Adamant-1-yl-3,7-dihydro-3-isopropyl-7-oxo-2H-[1,4]oxazino[2,3,4-
ij]quinoline-6-carboxamide  
White solid. Mp: 220 °C. Yield: 53%. MS: m/z 407.5 (M + H). 
1
H NMR (DMSO-d6): δ 
9.90 (br s, 1H), 8.68 (s, 1H), 7.85–7.81 (m, 1H), 7.42–7.28 (m, 2H), 4.79–4.73 (m, 1H), 
4.42–4.24 (m, 2H), 2.04 (s, 10H), 1.92 (m, 1H), 1.65 (s, 6H), 0.99 (d, J = 6.6 Hz, 3H), 
0.75 (d, J = 6.6 Hz, 3H). Anal. (C25H30N2O3) C, H, N. [α]D
25
 = −42 (c = 0.01, CH3OH). 
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(R)-108 (R)-(+)-N-Adamant-1-yl-3,7-dihydro-3-isobutyl-7-oxo-2H-[1,4]oxazino[2,3,4-
ij]quinoline-6-carboxamide  
White solid. Mp: 130 °C. Yield: 28%. MS: m/z 421.3 (M + H). 
1
H NMR (DMSO-d6): δ 
9.92 (br s, 1H), 8.67 (s, 1H), 7.88–7.83 (m, 1H), 7.45–7.32 (m, 2H), 4.82–4.75 (m, 1H), 
4.63–4.57 (m, 1H), 4.35–4.24 (m, 1H), 2.07 (s, 10H), 1.68 (s, 6H),1.44 (m, 1H), 0.99 (d, 
J = 5.8 Hz, 3H), 0.90 (d, J = 5.8 Hz, 3H). Anal. (C26H32N2O3) C, H, N. 
(R)-109 (R)-(+)-N-Adamant-1-yl-3-benzyl-3,7-dihydro-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide  
White solid. Mp: 153 °C. Yield: 55%. MS: m/z 455.6 (M + H). 
1
H NMR (DMSO-d6): δ 
9.85 (br s, 1H), 8.50 (s, 1H), 7.89–7.85 (m, 1H), 7.43–7.19 (m, 7H), 4.99 (m, 1H), 4.41–
4.23 (m, 2H), 3.04 (d, J = 7.4 Hz, 2H), 2.03 (s, 9H), 1.66 (s, 6H). Anal. (C29H30N2O3) C, 
H, N. [α]D
25
 = +190 (c = 0.01, CH3OH). 
 
Synthesis of N-Adamant-1-yl-3,7-dihydro-3-ethyl-10-methoxy-7-oxo-2H-[1,4] 
oxazino[2,3,4-ij]quinoline-6-carboxamide (105) 
 
A solution of N-adamant-1-yl-3,7-dihydro-3-ethyl-10-fluoro-7-oxo-2H-[1,4]oxazino 
[2,3,4-ij]quinoline-6-carboxamide (103; 0.14 mmol) in dry THF (3 mL) was added to a 
solution of freshly prepared CH3ONa (0.28 mmol) under a nitrogen atmosphere. The 
reaction mixture was heated at 50 °C for 16 h and neutralized using 1 N HCl. The 
mixture was concentrated in vacuo and the residue extracted with CH2Cl2. The organic 
layer was washed with brine, dried over Na2SO4, filtered, and evaporated to dryness. 
The crude residue was purified by chromatography using petroleum ether/ethyl acetate 
(1/1) as the eluent. 
 
105 N-adamant-1-yl-3,7-dihydro-3-ethyl-10-methoxy-7-oxo-2H-[1,4]oxazino[2,3,4-ij] 
quinoline-6-carboxamide 
White solid. Mp: 279 °C. Yield: 33%. MS: m/z 423.1 (M + H). 
1
H NMR (CDCl3): δ 
9.98 (br s, 1H), 8.59 (s, 1H), 8.07 (d, J = 9 Hz, 1H), 7.12 (d, J = 9 Hz, 1H), 4.65–4.59 
(m, 1H), 4.30–4.21 (m, 1H), 4.19 (m, 1H), 4.02 (s, 3H), 2.16–2.10 (m, 9H), 1.91–1.88 
(m, 2H), 1.73 (m, 6H), 1.05 (t, J = 7.4 Hz, 3H). Anal. (C25H30N2O3) C, H, N. 
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Synthesis of N-Adamant-1-yl-3,7-dihydro-3-ethyl-7-oxo-10-pyrrolidin-1-yl-2H-
[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide (106) 
 
K2CO3 (1 mmol) was added to a mixture of N-adamant-1-yl-3,7-dihydro-3-ethyl-10-
fluoro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide (103; 0.36 mmol), 
pyrrolidine (2.5 mmol), and anhydrous DMF (5 mL). The resulting mixture was stirred 
at 100 °C for 10 h. The solvent was removed under vacuum, the residue dissolved in 
ethyl acetate (30 mL), and the organic layer washed with water (5 mL). The organic 
phase was dried over anhydrous sodium sulfate, filtered, evaporated, and purified by 
flash chromatography using ethyl acetate/petroleum ether (3/7) as the eluent.  
Pale white solid. Mp: 282 °C. Yield: 50%. MS: m/z 462.4 (M + H). 
1
H NMR (CDCl3): δ 
10.01 (br s, 1H), 8.50 (s, 1H), 7.71 (d, J = 9 Hz, 1H), 6.80 (d, J = 9.2 Hz, 1H), 4.532–
4.38 (m, 2H), 4.14–4.07 (m, 1H), 3.51 (m, 4H), 2.06 (s, 9H), 1.96–1.73 (m, 6H), 1.66 (s, 
6H), 0.96 (t, J = 7.4 Hz, 3H). Anal. (C28H35N3O3) C, H, N. 
 
Synthesis of N-Adamant-1-yl-3,7-dihydro-3-ethyl-7-oxo-10-(4-methylpiperazin-1-
yl)-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide (107) 
 
K2CO3 (1 mmol) was added to a mixture of N-adamant-1-yl-3,7-dihydro-3-ethyl-10-
fluoro-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide (103; 0.36 mmol), 1-
methylpiperazine (2.5 mmol), and anhydrous DMF (5 mL). The resulting mixture was 
stirred at 100 °C for 10 h. The solvent was removed in vacuo, the residue dissolved in 
ethyl acetate (30 mL), and the organic layer washed with water (5 mL). The organic 
phase was dried over anhydrous sodium sulfate, filtered, evaporated, and purified by 
flash chromatography using ethyl acetate/petroleum ether (3/7) as the eluent.  
White solid. Mp: 294 °C dec. Yield: 40%. MS: m/z 491.3 (M + H). 
1
H NMR (DMSO-
d6): δ 9.95 (s, 1H), 8.61 (s, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.12 (d, J = 8.6 Hz, 1H), 4.75–
4.67 (m, 2H), 4.45–4.38 (m, 1H), 3.25–3.11 (m, 4H), 2.49–2.46 (m, 4H), 2.21 (s, 3H), 
2.03 (s, 9H), 1.84–1.69 (m, 2H), 1.65 (s, 6H), 0.93 (t, J = 7.4 Hz, 3H). 
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Synthesis of N-Adamant-1-yl-3-ethyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-
dihydro-2H-[1,4]-oxazino[2,3,4-ij]quinoline-6-carboxamide Hydrochloride 
(107·HCl) 
 
A solution of N-adamant-1-yl-3-ethyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-
7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamide (107, 0.04 mmol) in 1,4-dioxane 
saturated with gaseous hydrogen chloride (4 mL) was stirred at 0 °C for 30 min. The 
solvent was concentrated in vacuo, and the residue was suspended in diethyl ether (10 
mL), filtered, and washed with cold diethyl ether. Pale yellow solid. Mp: 240 °C dec. 
Yield: 69%. MS: m/z 527.8 (M + H). 
1
H NMR (DMSO-d6): δ 10.48 (br s, 1H), 9.94 (s, 
1H), 8.67 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H), 4.68–4.57 (m, 2H), 
4.30–4.25 (m, 1H), 3.70–2.88 (m, 11H), 2.05 (m, 9H), 1.67 (m, 8H), 0.92 (t, J = 7.4 Hz, 
3H). Anal. (C29H39ClN4O3) C, H, N. 
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